<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> BIOCRYST PHARMACEUTICALS INC (Form: 10-K, Received: 02/26/2016 16:51:50) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_COMPENSATION **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_BALANCE_SHEET **FIS_CASH_FLOW **FIS_STOCKHOLDERS_EQUITY **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_AUDITORS_OPINION **FIS_AUDITORS_OPINION_2 **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_21 **FIS_SUBSIDIARIES FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="103">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="F10K_022616P_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Washington,&nbsp;D.C. 20549
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	________________________
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Form 10-K
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	________________________
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9746;
</FONT>
</TD>
<TD STYLE="WIDTH: 96%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	For the fiscal year ended December&nbsp;31, 2015
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	OR
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 96%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Commission File Number 000-23186
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	________________________
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(Exact name of registrant as specified in its charter)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	________________________
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 47%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 52%; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DELAWARE
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	62-1413174
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.6PT 0PT 0">
<B>
	(State of other jurisdiction of
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.6PT 0PT 0">
<B>
	incorporation or organization)
</B>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.6PT 0PT 0">
<B>
	(I.R.S. employer
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.6PT 0PT 0">
<B>
	identification no.)
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(Address of principal executive offices)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(919)&nbsp;859-1302
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(Registrant&#8217;s telephone number, including area code)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Securities registered pursuant to Section&nbsp;12(b) of the Act:
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 47%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 52%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	Title of Each Class
</U>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	Name of Each Exchange on Which Registered
</U>
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Common Stock, $.01&nbsp;Par Value
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	The NASDAQ Global Select Market
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Securities registered pursuant to Section&nbsp;12(g) of the Act:
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Title of class
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	None
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	________________________
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined
	in Rule&nbsp;405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Indicate by a check mark if the registrant is not required to file reports pursuant
	to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by a check mark whether the registrant (1)&nbsp;has filed
	all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months
	(or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing
	requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Indicate by a check mark whether the registrant submitted electronically and posted
	on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of
	Regulation&nbsp;S-T (Section&nbsp;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that
	the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark if disclosure of delinquent filers pursuant
	to Item&nbsp;405 of Regulation&nbsp;S-K (Section&nbsp;229.405 of this chapter) is not contained herein, and will not be contained,
	to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III
	of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;&#9744;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated
	filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.
	(Check one):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 24%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 44%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 26%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9746;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Accelerated&nbsp;filer
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-accelerated filer
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Smaller&nbsp;reporting&nbsp;company
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Indicate by a check mark whether the registrant is a shell company (as defined in Exchange
	Act Rule 12b-2).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9746;.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	The Registrant estimates that the aggregate market value of the Common Stock on June&nbsp;30,
	2015 (based upon the closing price shown on the NASDAQ Global Select Market on June&nbsp;30, 2015)&nbsp;held by non-affiliates
	was $1,078,490,079.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	The number of shares of Common Stock, par value $.01, of the Registrant outstanding
	as of January&nbsp;31, 2016 was 73,629,816 shares.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Portions of the Registrant&#8217;s definitive Proxy Statement to be filed in connection
	with the solicitation of proxies for its 2016 Annual Meeting of Stockholders are incorporated by reference into Items&nbsp;10,
	11, 12, 13 and 14 under Part&nbsp;III hereof.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 100%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<B>
<U>
	TABLE OF CONTENTS
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 97%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART&nbsp;I
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_001">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;1.
	BUSINESS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_001">
<FONT STYLE="FONT-SIZE: 10PT">
	4
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_002">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;1A.
	RISK FACTORS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_002">
<FONT STYLE="FONT-SIZE: 10PT">
	19
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_003">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;1B.
	UNRESOLVED STAFF COMMENTS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_003">
<FONT STYLE="FONT-SIZE: 10PT">
	36
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_004">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;2.
	PROPERTIES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_004">
<FONT STYLE="FONT-SIZE: 10PT">
	37
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_005">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;3.
	LEGAL PROCEEDINGS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_005">
<FONT STYLE="FONT-SIZE: 10PT">
	37
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_006">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;4.
	MINE SAFETY DISCLOSURES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_006">
<FONT STYLE="FONT-SIZE: 10PT">
	37
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART&nbsp;II
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_007">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;
	5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_007">
<FONT STYLE="FONT-SIZE: 10PT">
	37
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_008">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;6.
	SELECTED FINANCIAL DATA
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_008">
<FONT STYLE="FONT-SIZE: 10PT">
	39
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_009">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;7.
	MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_009">
<FONT STYLE="FONT-SIZE: 10PT">
	39
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_010">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;7A.
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_010">
<FONT STYLE="FONT-SIZE: 10PT">
	52
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_011">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;8.
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_011">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_019">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;9.
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_019">
<FONT STYLE="FONT-SIZE: 10PT">
	81
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_020">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;9A.
	CONTROLS AND PROCEDURES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_020">
<FONT STYLE="FONT-SIZE: 10PT">
	81
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_021">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;9B.
	OTHER INFORMATION
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_021">
<FONT STYLE="FONT-SIZE: 10PT">
	81
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART&nbsp;III
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_022">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;10.
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_022">
<FONT STYLE="FONT-SIZE: 10PT">
	82
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_023">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;11.
	EXECUTIVE COMPENSATION
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_023">
<FONT STYLE="FONT-SIZE: 10PT">
	82
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_024">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;12.
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_024">
<FONT STYLE="FONT-SIZE: 10PT">
	82
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_025">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;13.
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_025">
<FONT STYLE="FONT-SIZE: 10PT">
	82
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_026">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;14.
	PRINCIPAL ACCOUNTING FEES AND SERVICES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_026">
<FONT STYLE="FONT-SIZE: 10PT">
	82
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART&nbsp;IV
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_027">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM&nbsp;15.
	EXHIBITS, FINANCIAL STATEMENT SCHEDULES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_027">
<FONT STYLE="FONT-SIZE: 10PT">
	83
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_028">
<FONT STYLE="FONT-SIZE: 10PT">
	SIGNATURES
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_028">
<FONT STYLE="FONT-SIZE: 10PT">
	84
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; TEXT-DECORATION: NONE">
<A HREF="#F10K_022616P_HTM_A_029">
<FONT STYLE="FONT-SIZE: 10PT">
	INDEX TO EXHIBITS
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_029">
<FONT STYLE="FONT-SIZE: 10PT">
	85
</FONT>
</A>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-10.70
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-10.71
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-21
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-23
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-31.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-31.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-32.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-32.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	EX-101
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PART I
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F10K_022616P_HTM_A_001">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>
	BUSINESS
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Forward-Looking Statements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	This report includes forward-looking statements within the meaning
	of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
	in Section&nbsp;21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events
	or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts
	contained herein are forward-looking statements. We have based these forward-looking statements on our current expectations about
	future events. While we believe these expectations are reasonable, forward-looking statements are inherently subject to risks and
	uncertainties, many of which are beyond our control. Our actual results may differ materially from those suggested by these forward-looking
	statements for various reasons, including those discussed in this report under the heading &#8220;Risk Factors.&#8221; Given these
	risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements
	included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update
	any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future
	events or developments. When used in the report, unless otherwise indicated, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221;
	the &#8220;Company&#8221; and &#8220;BioCryst&#8221; refer to BioCryst Pharmaceuticals, Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Our Business
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We are a biotechnology company that designs, optimizes and develops
	novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
	in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
	crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
	known as structure-guided drug design. Structure-guided drug design is a drug discovery approach by which we design synthetic compounds
	from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. We use X-ray crystallography,
	computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure
	and active site characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many
	vital biological reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme and thereby
	prevent its catalytic activity. Molecules from our discovery efforts which are commercially available or that are in development
	are summarized in the table below:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 18%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Drug/Drug Candidate
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Drug Class
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Therapeutic
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Area(s)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Rights
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	RAPIVAB
<SUP>
	&#174;
</SUP>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(peramivir injection)
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Intravenous Neuraminidase Inhibitor
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Acute uncomplicated Influenza
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	Approved
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(US)
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
	Seqirus (worldwide, except Japan, Taiwan, Korea and Israel) BioCryst
	retains U.S. stockpiling rights
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	RAPIACTA
<SUP>
	&#174;
</SUP>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(peramivir injection)
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Intravenous Neuraminidase Inhibitor
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Uncomplicated seasonal influenza
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	Approved
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(Japan)
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	Shionogi
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(Japan &amp; Taiwan)
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	PERAMIFLU
<SUP>
	&#174;
</SUP>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(peramivir injection)
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Intravenous Neuraminidase Inhibitor
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Uncomplicated seasonal influenza
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	Approved
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(Korea)
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	Green Cross
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(Korea)
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Avoralstat
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	(previously BCX4161)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Oral Serine Protease Inhibitor Targeting Kallikrein
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Hereditary angioedema (&#8220;HAE&#8221;)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase 2/3
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	BioCryst
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(worldwide)
</P>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
	BCX7353
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
	&nbsp;
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
	Oral Serine Protease Inhibitor Targeting Kallikrein (intended to be a once-daily
	treatment)
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
	HAE
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
	Phase 2
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0.8PT 0PT 0">
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	BioCryst
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(worldwide)
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	Other 2
<SUP>
	nd
</SUP>
	generation&nbsp;
<BR>
	HAE compounds
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	Oral Serine Protease Inhibitors Targeting Kallikrein
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	HAE and other indications
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	Preclinical
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	BioCryst
<BR>
	(worldwide)
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 1.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	BCX4430
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	RNA dependent-RNA Polymerase Inhibitor
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Filoviruses, including Ebola and Marburg viruses
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase 1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	BioCryst
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(worldwide)
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 1.6PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forodesine
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Oral Purine Nucleoside Phosphorylase Inhibitor
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Oncology
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Preparing to file for regulatory approval
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	Mundipharma
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 1.6PT 0PT 0">
	(worldwide)
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Business Strategy
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Our business strategy is to create shareholder value by focusing
	our discovery and development efforts on oral drugs for rare diseases for which a significant unmet medical need exists. We select
	disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would
	be the first to market. We strive to advance our product candidate portfolio from discovery to commercial markets efficiently by
	utilizing a small group of talented and highly-skilled employees working in conjunction with strategic outsource partners. BioCryst
	is unique in its approach to treat orphan diseases with small molecules utilizing crystallography and structure-guided drug design.
	The principal elements of our strategy are:&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Focusing on High Value-Added Structure-Guided Drug Design Technologies.
</I>
	We utilize structure-guided drug design in order to most efficiently develop new therapeutic candidates. Structure-guided drug design is a process by which we design a product candidate through detailed analysis of the enzyme target, which the product candidate must inhibit in order to stop the progression of the disease or disorder. We believe that structure-guided drug design is a powerful tool for the efficient development of small-molecule product candidates that have the potential to be safe and effective. Our structure-guided drug design technologies typically allow us to design and synthesize multiple product candidates that inhibit the same enzyme target, with the goal of establishing broad patent protection and formulating compounds with competitive advantages.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Selecting Inhibitors that are Promising Product Candidates.
</I>
	We start by selecting disease targets with well-understood biology and characteristics that fit with our ability to utilize structure-guided drug design capabilities to build potent and specific enzyme inhibitors. Next, we narrow our selection of these product candidates based on product characteristics, such as initial indications of safety and biologic activity on the target.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Developing our Product Candidates Efficiently.
</I>
	An important element of our business strategy is to efficiently progress our product candidates through the development process. In order to accomplish this, we strive for disease targets with a defined clinical and regulatory pathway for approval. In addition, we control fixed costs and overhead by outsourcing with strategic partners and contractors or entering into license agreements with third parties, including the U.S. Government. We maintain a streamlined corporate infrastructure that focuses our expertise. By contracting with the U.S. Government and outsourcing certain aspects of our operations, we are able to control overhead costs and focus financial resources directly where they provide the most benefit and reduce our business risk.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	We are a Delaware corporation originally founded in 1986. Our corporate
	headquarters is located at 4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703 and the corporate telephone number
	is (919)&nbsp;859-1302. For more information about us, please visit our website at www.biocryst.com. The information on our website
	is not incorporated into this Form&nbsp;10-K.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<B>
	RAPIVAB (peramivir injection)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Peramivir is an intravenous neuraminidase inhibitor approved in
	multiple countries for the treatment of patients with influenza, most recently in the United States as RAPIVAB
<SUP>
	&#174;
</SUP>
	.
	Influenza is a seasonal virus with the highest infection rates generally observed in colder months.&nbsp;Intravenous (&#8220;i.v.&#8221;)
	peramivir injection has also been approved in Japan (RAPIACTA
<SUP>
	&#174;
</SUP>
	) and Korea (PERAMIFLU
<SUP>
	&#174;
</SUP>
	). In the countries
	for which peramivir is commercially available, influenza occurs primarily during the September to April timeframe.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	RAPIVAB was approved by the U.S. Food and Drug Administration
	(&ldquo;FDA&rdquo;) on December 19, 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older
	who have been symptomatic for no more than two days. In December 2013, we submitted a New Drug Application
	(&ldquo;NDA&rdquo;) which contained data from over 2,700 subjects treated with peramivir in 27 clinical trials. We made
	RAPIVAB available for commercial sale through agreements with specialty distributorships during the 2014-2015 influenza
	season. On June 17, 2015, we announced that BioCryst licensed
<FONT STYLE="FONT-SIZE: 10PT">
	RAPIVAB (peramivir injection) for
	the treatment of influenza to CSL Limited (&ldquo;CSL&ldquo;), a global biopharmaceutical company. RAPIVAB is being commercialized by a
	subsidiary of CSL called Seqirus UK Limited (&ldquo;SUL&rdquo;), which specializes in influenza prevention through the
	supply of seasonal and pandemic influenza vaccine to global markets. Under the terms of the agreement, SUL obtained worldwide
	rights to commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retained all rights to
	pursue pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL is responsible for government stockpiling
	outside the U.S. With the out-license of RAPIVAB to SUL, a strategic and well-suited commercialization partner, our current
	goals for RAPIVAB are to: (1) obtain a stockpiling procurement contract with the U.S. Government to realize the strategic
	value of this program; (2) fulfill our post-approval development requirements, including conducting a pediatric trial; and
	(3) submit a Marketing Authorization Application (&ldquo;MAA&rdquo;) and New Drug Submission (&ldquo;NDS&rdquo;) in the
	European Union and Canada, respectively, to allow SUL the ability to commercialize the drug in those regions.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In January 2016, we filed a NDS with Health Canada for RAPIVAB as
	an i.v. treatment for acute, uncomplicated influenza.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	RAPIVAB was developed under a $234.8 million contract from the Biomedical
	Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8220;BARDA/HHS&#8221;),
	which expired on June 30, 2014. See &#8220;Collaborations and In-License Relationships&#8212;BARDA/HHS&#8221; below for a further
	discussion of this development contract.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In January 2010, our partner Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;)
	received the first approval for peramivir injection and launched it in Japan under the commercial name RAPIACTA. It was initially
	approved for the treatment of adults with uncomplicated seasonal influenza, as well as those at high-risk for complications associated
	with influenza. In October 2010, Shionogi received approval for an additional indication to treat children and infants with influenza
	in Japan. In August 2010, Green Cross Corporation (&#8220;Green Cross&#8221;) received marketing and manufacturing approval from
	the Korean Food&nbsp;&amp; Drug Administration under the commercial name PERAMIFLU to treat patients with influenza A &amp; B viruses,
	including pandemic H1N1 and avian influenza. In addition, we have a regional collaboration for the development and commercialization
	of peramivir in Israel.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Hereditary Angioedema Drug Candidates
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
<U>
	Avoralstat
</U>
	:
</I>
	Avoralstat is our most advanced hereditary
	angioedema (&#8220;HAE&#8221;) product candidate in a suite of molecules being developed as oral treatments for the prevention
	of HAE attacks. Avoralstat is positioned to be the first oral prophylactic kallikrein inhibitor for the prevention of HAE attacks.
	Avoralstat is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention
	of attacks in patients with HAE. By inhibiting plasma kallikrein, avoralstat suppresses bradykinin production. Bradykinin is the
	mediator of acute swelling attacks in HAE patients. HAE is a rare, severely debilitating and potentially fatal genetic condition
	that occurs in approximately 1 in 50,000 people. HAE symptoms include recurrent episodes of edema in various locations, including
	the hands, feet, face, genitalia and airway. Airway swelling is particularly dangerous and can lead to death by asphyxiation. In
	addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting caused by swelling in the intestinal wall.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	In December 2014 and January 2015, respectively, the FDA granted
	avoralstat &#8220;Orphan Drug&#8221; designation and &#8220;Fast Track&#8221; designation for the treatment of HAE. Orphan drug
	designation is granted by the FDA Office of Orphan Products Development to novel drugs intended for the safe and effective treatment
	of a rare disease or condition that affects fewer than 200,000 patients in the U.S. This designation provides certain incentives,
	including federal grants, tax credits, waiver of Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) filing fees, and a seven-year
	marketing exclusivity period against competition once the product candidate is approved. The Fast Track designation process of
	the FDA is designed to facilitate the development and expedite the review and approval of drugs intended to treat serious or life
	threatening conditions and that address unmet medical needs. A drug that receives Fast Track designation is usually eligible for
	more frequent written communication and meetings with the FDA to discuss the drug's development plan and the collection of appropriate
	data supporting drug approval. In addition, the Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) of the European Medicines
	Agency (&#8220;EMA&#8221;) issued a positive opinion on the application for orphan drug designation for avoralstat for the treatment
	of patients with HAE and the European Commission recently affirmed this designation. Orphan drug designation by the EMA provides
	regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically
	debilitating condition affecting no more than five in 10,000 persons in the European Union (&#8220;EU&#8221;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On December 18, 2014, we announced the dosing of the first patient
	in OPuS-2 (
<B>
	O
</B>
	ral
<B>
	P
</B>
	rophylaxi
<B>
	S-2
</B>
	), a blinded, randomized, placebo-controlled clinical trial of orally-administered
	avoralstat in patients with HAE. OPuS-2 was a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety
	of two doses of avoralstat, 300 mg and 500 mg, administered three-times daily compared with placebo. This trial was conducted
	in the U.S. and select European countries, and it enrolled approximately 100 HAE patients. The primary goals of the trial were
	to characterize the efficacy of avoralstat in reducing the frequency of angioedema attacks, and to evaluate the safety and tolerability
	of 12 weeks of avoralstat treatment. The primary efficacy endpoint was angioedema attack frequency.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	On February 8, 2016, we announced
	results from OPuS-2.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	In the OPuS-2 study, HAE patients with a historical attack frequency
	of greater than 0.45 attacks per week were randomized to treatment with either 500 mg or 300 mg of avoralstat, or placebo, administered
	three times daily for 12 weeks. Thirty-eight subjects received avoralstat 500 mg, 36 subjects received avoralstat 300 mg, and 36
	subjects received placebo. Treatment with 500 mg and 300 mg of avoralstat three times daily failed to demonstrate a statistically
	significantly lower mean attack rate versus placebo. The mean (standard deviation) attack rates per week were 0.63 (0.57) on avoralstat
	500 mg and 0.71 (0.66) on avoralstat 300 mg, compared to 0.61 (0.41) on placebo.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Statistically
	significant improvements in duration of attacks and in the Angioedema Quality of Life total score were observed comparing the 500
	mg three times a day avoralstat arm to placebo. Following the analysis of OPuS-2 results, the decision was made to discontinue
	further development of softgel avoralstat formulation in order to focus development efforts on a novel solid dosage form of avoralstat
	to achieve meaningfully better drug exposure. We expect additional avoralstat results from a relative bioavailability study testing
	a novel solid dosage form of avoralstat by mid-year 2016. The primary goals of this study are to achieve meaningfully better drug
	exposures and twice daily dosing.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	On May 27, 2014, we announced positive results from a Phase 2a
	proof of concept OPuS-1(
<B>
	O
</B>
	ral
<B>
	P
</B>
	rophylaxi
<B>
	S-1
</B>
	) clinical trial in patients with HAE. This clinical trial evaluated
	400 mg of avoralstat administered three-times daily for 28 days in a randomized, placebo-controlled, two-period cross-over design.
	Twenty-four HAE patients who had a high frequency of attacks (more than one per week) were enrolled. This study was designed to
	provide proof of concept for oral kallikrein inhibition as a treatment strategy for HAE. The primary goals of the trial were to
	estimate the degree of efficacy of avoralstat in reducing the frequency of angioedema attacks and to evaluate the safety and tolerability
	of 28 days of avoralstat treatment. The OPuS-1 trial met its primary efficacy endpoint, several secondary endpoints as well as
	other objectives established for the clinical trial. Each of the twenty-four patients dosed completed the trial. The primary efficacy
	endpoint for the trial was the mean angioedema attack rate. Treatment with avoralstat demonstrated a statistically significant
	mean attack rate reduction of 0.45 attacks per week versus placebo, p&lt; 0.001. The mean attack rate per week was 0.82 on avoralstat
	treatment, compared to 1.27 on placebo. Oral administration of avoralstat was generally safe and well-tolerated, with an adverse
	event profile similar to that observed for placebo. Patient dosing compliance in this trial was 98 percent.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
<U>
	2nd generation HAE compounds:
</U>
</I>
	The goal of our second
	generation HAE discovery program is to discover and develop oral molecules for the prevention of HAE attacks which have a superior
	selectivity and bioavailability profile while maintaining similar potency as compared to avoralstat. In December 2013, we announced
	the selection of two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral
	prophylactic treatments for HAE. Based on early preclinical development studies, these structurally different molecules have a
	similar mechanism of action as avoralstat and have achieved the principal goal of improved bioavailability. Both BCX7353 and the
	second compound had roughly five times better bioavailability than avoralstat. These compounds demonstrated sub-nanomolar potency
	on the isolated enzyme and single digit nanomolar potency in suppressing kallikrein activity in an ex-vivo activated normal human
	plasma kallikrein inhibition (&ldquo;aPKI&rdquo;) assay. Plasma concentrations of each of the optimized compounds exceeded the
	aPKI assay EC80 concentration at 24 hours after a single oral dose of 10 mg/kg in rats, indicating potential for once-daily dosing.
	In January 2015, we selected BCX7353 to advance into Phase 1 development as a once-daily, oral prophylactic HAE treatment. Given
	the other advanced second generation molecule&rsquo;s inferior profile and similar molecular composition to BCX7353, we have chosen
	only to advance BCX7353. In addition to BCX7353, we continue to work on and advance other second generation compounds that are
	at an earlier stage. These molecules are in preclinical development and will be assessed for safety and efficacy in prophylactic
	HAE treatment as well as for other potential indications. We will provide additional information on these molecules as we approach
	an Investigational New Drug (&ldquo;IND&rdquo;) filing or we obtain data suggesting efficacy and safety surrounding these molecules
	in potential HAE and other therapeutic indications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
<U>
	BCX7353
</U>
</I>
	: BCX7353 is structurally different from avoralstat,
	but has a similar mechanism of action targeting plasma kallikrein. On May 13, 2015, we announced the initiation of a Phase 1 clinical
	trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 12PT 0 0">
	On October 8, 2015, we announced that the randomized, placebo-controlled,
	Phase 1 clinical trial of orally-administered BCX7353 in healthy volunteers successfully met all of its objectives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	In this Phase 1 clinical trial BCX7353 dose levels included
	single doses of up to 1000mg, once-daily doses of up to 500 mg for seven days, and once-daily doses of 350 mg for 14 days. Plasma
	levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with food. The half-life of BCX7353
	was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target therapeutic range throughout
	the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay.
	Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the degree of inhibition was dose-related
	(p &lt; 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This pharmacodynamic effect correlated strongly
	to the achieved drug concentration (r = 0.91, p &lt; 0.0001).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	Subsequently, cohorts of healthy Japanese volunteers were added
	to the study to support development of BCX7353 in Japan under the &ldquo;Sakigake&rdquo; accelerated R&amp;D designation. Following assessment
	of single oral doses of BCX7353 of 100mg (6 subjects) and 500 mg (6 subjects), 250 mg of BCX7353 was administered orally and daily
	for seven days to ten subjects. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects
	were moderately higher. Kallikrein inhibition on day seven of daily dosing with 250 mg in Japanese subjects was similar to that
	seen at the 350 mg daily and 500 mg daily dose levels in Western subjects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	The combined data from both Western and Japanese healthy volunteers
	indicates that oral BCX7353 has been generally safe and well tolerated in a total of 96 treated healthy volunteers, 46 with singles
	doses and 50 with multiple doses. No serious adverse events have been seen and no dose-limiting toxicity has been identified. There
	have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	In single dose subjects, 89% (31 of 35) of adverse events (AEs)
	have been grade 1. The four grade 2 AEs observed were: nausea (1) and vomiting (1) occurring in one subject: hay fever (1) and
	diarrhea (1 from Japanese cohort).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	In multiple dose subjects, 90% (63 of 70) of adverse
	events (AEs) have been grade 1. The six grade 2 AEs observed were: upper abdominal pain (1, discontinued from study); syncope
	(1) headache (1) diarrhea (1) and upper abdominal pain (1) occurring on one subject (discounted from study), and
	maculopapular rash. One grade 3 AE was observed, a cutaneous delayed-type hypersensitivity reaction. The two rash AE&rsquo;s
	are described in more detail below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	The incidence of drug-related skin rash across all multiple-dose
	cohorts was 4% (2 of 50 subjects). One Japanese subject dosed at 250 mg daily for seven days developed a grade 2 maculopapular
	skin rash following cessation of dosing, and one Western subject dosed at 500 mg daily for seven days developed a grade 3 hypersensitivity
	reaction, described as a maculopapular skin rash, following cessation of dosing. Both AEs were assessed by the investigator as
	drug-related. The Japanese subject received antihistamines and the Western subject received corticosteroids, and in both cases
	the rash resolved within a few days.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	The safety, tolerability, drug exposure and on-target plasma
	kallikrein inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase
	2 trial (&ldquo;APeX-1&rdquo;) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353
	as a preventative treatment to reduce the frequency of attacks in HAE patients is expected to begin in 2016. The design of the
	trial will be described when the APeX-1 protocol is approved by regulatory authorities and the clinical trial is initiated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	On October 27, 2015 The Japanese Ministry of Health Labor &amp;
	Welfare (&ldquo;MHLW&rdquo;) announced that BioCryst&rsquo;s BCX7353 was one of six products designated under MLHW&rsquo;s new
	Sakigake fast track review system. The Sakigake Designation System promotes R&amp;D in Japan, aiming at early market
	availability for innovative pharmaceutical products. This designation provides for additional interactions with the regulatory
	agency in Japan from early development through filing, prioritized development and review, and introduction of the product as
	soon as possible to address a serious unmet medical need. We expect the results of APeX-1 to help us and the MHLW to determine
	the regulatory pathway and timeline for BCX7353 in Japan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	BCX4430
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	BCX4430 is a broad-spectrum antiviral (&ldquo;BSAV&rdquo;) research
	program and is currently being developed under contracts with the National Institute of Allergy and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;)
	and the U.S.&nbsp;Department of Health and Human Services (&ldquo;BARDA/HHS&rdquo;). The objective of our BSAV program is to develop
	BCX4430 as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The primary focus of the
	program is treatment of hemorrhagic fever viruses. NIAID/HHS funding has supported BCX4430&rsquo;s development as a treatment
	for Marburg virus and Ebola virus. In March 2014, BCX4430 was featured in an online
<I>
	Nature
</I>
	publication depicting successful
	efficacy results in animal models of infection with Marburg virus and Ebola virus.&nbsp;BCX4430 completely protected cynomolgus
	macaques from Marburg virus infection when administered by intramuscular (&ldquo;i.m.&rdquo;) injection 48 hours post-infection.&nbsp;Post-exposure
	i.m. administration of BCX4430 also protected rodents against Marburg virus and Ebola virus infections.&nbsp;In addition, BCX4430
	was shown to be active in vitro against a broad range of other RNA viruses, including the emerging viral pathogen Middle East
	Respiratory Syndrome Coronavirus (&ldquo;MERS-CoV&rdquo;).&nbsp;The publication, which reported the protection of non-human primates
	from filovirus disease by BCX4430, describes efficacy results generated from an ongoing collaboration between scientists in the
	U.S. Army Medical Research Institute of Infection Diseases (&ldquo;USAMRIID&rdquo;) and us.&nbsp;BCX4430 has been shown to be
	active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses,
	paramyxoviruses, coronaviruses and flaviviruses.&nbsp;In tests conducted at USAMRIID, BCX4430 protected animals against parenteral
	exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition
	designed to mimic an exposure scenario that could result during a bioterrorist attack.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On December 23, 2014, we announced results from a successful proof-of-concept
	study of BCX4430 for the treatment of experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary
	goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus.
	Dosing of&nbsp;placebo or BCX4430 by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice a day
	(&#8220;BID&#8221;) for 14 days. Animals were dosed with either placebo, 16 mg/kg of BCX4430 BID or 25 mg/kg of BCX4430 BID. Survival
	at day 41 in the 16 mg/kg BID group of BCX4430 treated animals was 4 of 6 (66.7%, p &lt; 0.001 compared to 0% survival in controls)
	and 6 of 6 in the 25 mg/kg BID group (100%, p &lt; 0.001 compared to controls). The overall survival rate for BCX4430 treated animals
	at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls). Preliminary evaluation of the quantity of virus in the blood showed
	an approximate 3-log reduction in Ebola virus RNA copies/mL of plasma, compared with control animals. This Rhesus macaque study
	was conducted following the completion, in November 2014, of a dose-ranging study of BCX4430 for the experimental treatment of
	cynomolgus macaques infected with Ebola virus. The cynomolgus macaque study was designed to evaluate whether BCX4430 showed a meaningful
	benefit for survival in Ebola virus non-human primate (&#8220;NHP&#8221;) disease models and explore a dose range. In this study
	BCX4430 demonstrated a statistically significant prolongation of survival for the animals at the highest dose regimen tested, but
	no animals survived beyond 21 days.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On December 15, 2014, we announced the dosing of the first subject
	in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The
	main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
	administered via i.m. injection in healthy subjects. In part one of the study, subjects will receive a single dose of BCX4430;
	and then subjects will receive BCX4430 for seven days in the second part of the study. Up to six single-dose cohorts and four multiple-dose
	cohorts will be evaluated, with a total of up to 88 volunteers participating. This Phase 1 study is expected to continue in 2016.
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Forodesine
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 12PT 0 0">
	Forodesine is a Purine Nucleoside Phosphorylase
	(&ldquo;PNP&rdquo;) inhibitor in development by Mundipharma as a treatment for cancer under a world-wide license agreement.
	PNP is a purine salvage pathway enzyme. High doses of PNP inhibitors could be useful in the treatment of hematological
	malignancies. Mundipharma has received orphan drug status for forodesine, and following successful completion of a Phase 2
	pivotal study in recurrent/refractory peripheral T-cell lymphoma patients in Japan, is preparing to file for regulatory
	approval.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	On November&nbsp;11, 2011, we entered into an Amended and Restated
	License and Development Agreement (the &ldquo;Amended and Restated Agreement&rdquo;) with Mundipharma, amending and restating the
	February&nbsp;1, 2006 exclusive, royalty-bearing Development and License Agreement for the development and commercialization of
	forodesine for use in the field of oncology. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide
	rights to forodesine, so Mundipharma controls the worldwide development and commercialization of forodesine and assumes all future
	development and commercialization costs. The Amended and Restated Agreement is a multiple element arrangement for accounting purposes
	in which we were required to deliver to Mundipharma both the worldwide rights to forodesine and the transfer of product data and
	know-how to permit Mundipharma to develop and commercialize forodesine (the &ldquo;Knowledge Transfer&rdquo;). The world-wide license
	rights were granted to Mundipharma upon execution of Amended and Restated Agreement and the Knowledge Transfer was completed in
	the first quarter of 2012.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	We have licensed the PNP technology from Albert Einstein College
	of Medicine of Yeshiva University (&#8220;AECOM&#8221;) and Industrial Research, Ltd. (&#8220;IRL&#8221;) and will owe sublicense
	payments to AECOM/IRL based on the future milestone payments and royalties received by us from Mundipharma and any other partners
	for which we out-license our PNP inhibitors. On November&nbsp;17, 2011, we amended our agreement with AECOM/IRL whereby AECOM/IRL
	agreed to accept a reduction of one-half of the percentage of Net Proceeds (as defined in the license agreement) received by us
	under our Amended and Restated Agreement with Mundipharma. This reduction does not apply to royalty payments made as a result of
	sales of licensed products by our sub licensees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Collaborations and In-License Relationships
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
<I>
<U>
	U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;)
</U>
	.
</I>
	In January 2007, BARDA/HHS awarded us a $102.6 million, four-year contract for the advanced development of peramivir for the
	treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment
	of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir
	program and to increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had awarded us a $55.0
	million contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients
	hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234.8 million and
	provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013,
	we submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired
	on June 30, 2014 according to its terms.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	On March 31, 2015, we announced that BARDA/HHS awarded us a contract
	for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
	BARDA/HHS contract includes a base contract of $13.3 million to support BCX4430 drug manufacturing, as well as $22.9 million in
	additional development options that can be exercised by the government, bringing the potential value of the contract to $36.2 million.
	As of December 31, 2015, a total of $16.3 million has been awarded under exercised options within this contract.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
<I>
<U>
	National Institute of Allergy and Infectious Diseases
	(&#8220;NIAID/HHS&#8221;)
</U>
	.
</I>
	In September 2013, NIAID/HHS contracted with us for the development of BCX4430 as a
	treatment for Marburg, and subsequently, Ebola virus disease. NIAID/HHS, part of the National Institutes of Health, made an
	initial award of $5.0 million to us. A total of $29.9 million of initial and option funding has been awarded under the
	NIAID/HHS contract to date and total funding under the contract could be up to $34.0 million, if all contract options are
	exercised. The goals of this contract, including amendments, are to file IND applications for i.v. and i.m. BCX4430 for the
	treatment of Marburg virus disease, to conduct an initial Phase 1 human clinical trial, as well as to study BCX4430 as a
	treatment for Ebola virus disease.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
	contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
	that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic
	assessments of progress and the continuation of the contract is based on our performance, the timeliness and quality of deliverables,
	and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
	by the government at any time for breach or without cause.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Seqirus UK Limited
</U>
	.
</I>
	On June 16, 2015, we and SUL,
	a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the
	laws of Australia, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights
	to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to
	conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory").
	RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan
	and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug
	Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been
	symptomatic for no more than two days. We retain all rights and associated economics to procure pandemic stockpiling orders for
	RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Pursuant to the SUL Agreement, RAPIVAB will be commercialized by
	CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global
	markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
	of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole
	decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible
	for all associated costs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In December 2013, we submitted a NDA for RAPIVAB to the FDA. Under
	the terms of the SUL Agreement, we are responsible for fulfilling all post-marketing approval commitments in connection with the
	FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant
	to potential rights to sell RAPIVAB in Canada and the EU, we are also responsible for regulatory filings and interactions with
	the Health Canada and the European Medicines Agency until marketing approval for RAPIVAB is obtained and assigned
	to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering committee, composed of an equal number of representatives
	from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory
	and any additional development.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Under the terms of the SUL Agreement, we received an upfront payment
	of $33.7 million, and may receive up to $12.0 million in additional milestone payments related to the successful achievement of
	regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication
	in the EU and (iii) by Health Canada for an adult indication in Canada. We are also entitled under the SUL Agreement to receive
	tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
	as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, we receive
	tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined
	as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory,
	other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting
	the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country
	basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement
	(the "Royalty Term"). We developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future
	milestone payments and/or royalties received by us from SUL.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	The term of the SUL Agreement shall continue on a country-by-country
	basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate
	the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement,
	subject to applicable cure periods, or if the other party suffers an insolvency event. We may also terminate the SUL Agreement
	if SUL or any of its affiliates seek to challenge the validity of our patents. Termination does not affect a party's rights which
	have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations
	previously accrued. For all terminations exercised by us, the SUL Agreement provides for the termination of any sublicenses granted
	by SUL to third parties, and in the case of termination by us for cause, the ceasing of SUL's activities with respect to RAPIVAB,
	the discontinued use of all of our intellectual property and the termination of licenses and rights previously granted to SUL.
	If requested by us, SUL shall also promptly sell to us all licensed product it then holds in stock, otherwise, SUL may continue
	to sell such licensed product for designated periods.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;)
</U>
	.
</I>
	On February&nbsp;28, 2007, we entered into a License, Development and Commercialization Agreement (as amended, supplemented or
	otherwise modified, the &#8220;Shionogi Agreement&#8221;), an exclusive license agreement with Shionogi to develop and commercialize
	peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. In October 2008, we and Shionogi
	amended the Shionogi Agreement to expand the territory covered by the agreement to include Taiwan. Under the terms of the Shionogi Agreement, Shionogi obtained rights to injectable
	formulations of peramivir in Japan in exchange for a $14.0&nbsp;million upfront payment. The license provided for development milestone
	payments (up to $21.0&nbsp;million), which have all been paid, and for commercial milestone payments (up to $95.0&nbsp;million)
	in addition to double-digit (between 10% and 20%) royalty payments on product sales of peramivir.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Generally, all payments under the Shionogi Agreement are non-refundable
	and non-creditable, but they are subject to audit. Shionogi is responsible for all development, regulatory, and marketing costs
	in Japan. The term of the Shionogi Agreement is from February&nbsp;28, 2007 until terminated. Either party may terminate in the
	event of an uncured breach. Shionogi has the right of termination without cause. In the event of termination, all license and rights
	granted to Shionogi shall terminate and shall revert back to us. We developed peramivir under a license from the University of
	Alabama Birmingham (&#8220;UAB&#8221;) and have paid sublicense payments to UAB on the upfront payments and will owe sublicense
	payments on any future event payments and/or royalties received by us from Shionogi.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Shionogi Royalty Monetization and Non-Recourse Notes Payable
</U>
</I>
	.
	On March&nbsp;9, 2011, we completed a $30.0 million&nbsp;financing transaction to monetize certain future royalty and milestone
	payments under the Shionogi Agreement, pursuant to which JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;) a wholly-owned subsidiary
	of BioCryst, issued the PhaRMA Notes discussed below. We received net proceeds of $22.7 million&nbsp;from this transaction.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	As part of the transaction, we entered into a purchase and sale
	agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby we transferred to Royalty Sub, among other things, (i)&nbsp;its
	rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
	right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
	Hedge Agreement&#8221;) put into place by us in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese
	yen and milestone payments will be paid in U.S. dollars. Our collaboration with Shionogi was not impacted by this transaction.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On March 9, 2011, Royalty Sub completed a private placement to institutional
	investors of $30.0 million in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA Notes&#8221;).
	The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;), by
	and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable
	from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by us to Royalty
	Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per
	annum, payable annually in arrears on September&nbsp;1st of each year (the &#8220;Payment Date&#8221;). We remain entitled to receive
	any royalties and milestone payments related to sales of peramivir by Shionogi following repayment by Royalty Sub of the PhaRMA
	Notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Royalty Sub&#8217;s obligations to pay principal and interest on
	the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
	to the extent of our pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. We may, but are not obligated
	to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall
	on, the PhaRMA Notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In September&nbsp;2013, Royalty Sub paid $1.8 million of interest
	on the PhaRMA Notes from royalty payments received from RAPIACTA sales from the preceding four calendar quarters. This payment
	resulted in an obligation shortfall of approximately $2.4 million associated with accrued interest due September&nbsp;3, 2013.
	As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay
	all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the
	PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, interest began to accrue at 14%&nbsp;per annum
	on the interest shortfall of $2.4 million. In March, June and August of 2014, Royalty Sub paid additional interest of $446,000,
	$1.9 million and $70,000, respectively, bringing the shortfall down to $222,000 as of September 30, 2014. Under the terms of the
	Indenture, Royalty Sub&rsquo;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding
	Payment Date for the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, we have classified
	the PhaRMA Notes and related accrued interest as current liabilities on our balance sheet. As a result of the event of default
	under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral
	securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture
	in respect of the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue
	to us following repayment of the PhaRMA Notes and we might otherwise be adversely affected. Due to the non-recourse nature of the
	PhaRMA Notes, in the event of any potential acceleration or foreclosure, we believe the primary impact to us would be the loss
	of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, we may incur costs
	associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure
	or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub, we do not currently expect
	the event of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. As of
	December 31, 2015, the PhaRMA Notes remain in default.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	The Indenture does not contain any financial covenants. The Indenture
	includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
	Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
	typical for indentures used in structured financings of this type. The PhaRMA Notes are redeemable at the option of Royalty Sub
	at any time at a redemption price equal to 100% of the outstanding principal balance of the PhaRMA Notes being redeemed, plus accrued
	and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Foreign Currency Hedge
</U>
	.
</I>
	In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement
	to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency
	Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which we may be required
	to pay a premium in each year from 2016 through 2020. A payment of $2.0 million&nbsp;will be required if, on May&nbsp;18 of the
	relevant year, the U.S. dollar is worth 100 yen or less, as determined in accordance with the Currency Hedge Agreement.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	The Currency Hedge Agreement does not qualify for hedge accounting
	treatment; therefore, mark-to-market adjustments are recognized in our Consolidated Statement of Comprehensive Loss. Cumulative
	mark-to-market adjustments resulted in a loss of $0.6 million and gains of $5.5 million and $5.3 million for the twelve months
	ended December&nbsp;30, 2015, 2014 and 2013, respectively. In addition, a realized currency exchange gain of $1.6 million was recognized
	in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. Thus, a resulting
	$1.1 million net gain is recognized on our foreign currency derivative for 2015.We are also required to post collateral in connection
	with the mark-to-market adjustments based on defined thresholds. As of December 31, 2015, no collateral was posted under the Currency
	Hedge Agreement. We will not be required at any time to post collateral exceeding the maximum premium payments remaining payable
	under the Currency Hedge Agreement. The maximum amount of hedge collateral we would be required to post is $9.8 million. We are
	required to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Green Cross
</U>
	.
</I>
	In June 2006, we entered into an agreement
	with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible
	for all development, regulatory, and commercialization costs in Korea. We received a one-time license fee of $250,000. The license
	provides that we will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean
	government for stockpiling purposes. Furthermore, Green Cross will pay us a premium over its cost to supply peramivir for development
	and any future marketing of peramivir products in Korea. Both parties have the right to terminate in the event of an uncured material
	breach. In the event of termination, all rights, data, materials, products and other information would be transferred to us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In August 2010, we announced that Green Cross had received marketing
	and manufacturing approval from the Korean Food&nbsp;&amp; Drug Administration for i.v. peramivir, under the commercial name PERAMIFLU
<SUP>
	&#174;
</SUP>
	.
	PERAMIFLU is intended to treat patients with influenza A&nbsp;&amp; B viruses, including pandemic H1N1 and avian influenza. Green
	Cross received the indication of single dose administration of 300&nbsp;mg i.v. peramivir. Since PERAMIFLU&#8217;s approval, Green
	Cross has been in pricing discussions with the Korean National Health Insurance Corporation and has yet to agree to a formulary
	price. PERAMIFLU&#8217;s distribution to date has been limited to a case-by-case basis and significant sales have not occurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Other Peramivir Collaborations
</U>
	.
</I>
	In addition to our
	collaborations with Shionogi and Green Cross, in March 2011 we entered into an arrangement with Neopharm Scientific Limited, granting
	certain commercial and distribution rights for peramivir in Israel.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Mundipharma
</U>
	.
</I>
	In February 2006, we entered into an
	exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine,
	a PNP inhibitor, for use in oncology (the &#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma
	obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10.0&nbsp;million up-front payment.
	In addition, Mundipharma contributed $10.0&nbsp;million of the documented out-of-pocket development costs incurred by us in respect
	of the current and planned trials as of the effective date of the agreement, and Mundipharma would conduct additional clinical
	trials at their own cost up to a maximum of $15.0&nbsp;million. The Original Agreement provided for the possibility of future event
	payments totaling $155.0&nbsp;million for achieving specified development, regulatory and commercial events (including certain
	sales level amounts following a product&#8217;s launch) for certain indications. In addition, the Original Agreement provided that
	we would receive royalties (ranging from single digits to mid teens) based on a percentage of net product sales, which varies depending
	upon when certain indications receive NDA approval in a major market country and can vary by country depending on the patent coverage
	or sales of generic compounds in a particular country. Generally, all payments under the Original Agreement were nonrefundable
	and non-creditable, but they are subject to audit. We licensed forodesine and other PNP inhibitors from AECOM/IRL and will owe
	sublicense payments to AECOM/IRL on all milestone payments and royalties received by us from Mundipharma.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On November&nbsp;11, 2011, we entered into the Amended and Restated
	Agreement with Mundipharma. Under the terms of this Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine
	in the field of oncology. Mundipharma will control the development and commercialization of forodesine and assume all future development
	and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling
	$15.0&nbsp;million for achieving specified regulatory events for certain indications. In addition, the Amended and Restated Agreement
	provides that we will receive tiered royalties ranging from mid- to high-single digit percentages of net product sales in each
	country where forodesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing
	patent coverage and/or the availability of generic compounds in each country. Generally, all payments under the Amended and Restated
	Agreement are nonrefundable and non-creditable, but they are subject to audit.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Mundipharma will also have a right of exclusive negotiations with
	us for a limited period of time if they initiate negotiations for a specified backup PNP inhibitor. Otherwise, they will be able
	to participate in the same negotiations process we enter into with another company for the backup PNP inhibitor. The Amended and
	Restated Agreement will continue for the commercial life of the licensed products, but may be terminated by either party following
	an uncured material breach by the other party or in the event the pre-existing third party license with AECOM/IRL expires. It may
	be terminated by Mundipharma upon 60&nbsp;days written notice without cause or under certain other conditions as specified in the
	Amended and Restated Agreement. If Mundipharma terminates the Amended and Restated Agreement, Mundipharma would no longer have
	any rights in forodesine and the rights would revert back to us; provided, however, that in the event the we determine to subsequently
	use the data developed under the Amended and Restated Agreement for development and commercialization of forodesine in the field
	of oncology, then we would have to pay Mundipharma 150% of the cost of such data for such use.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Albert Einstein College of Medicine of Yeshiva University
	and Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively)
</U>
	.&nbsp;
</I>
	In June 2000, we licensed
	a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &ldquo;Licensors&rdquo;). The lead product candidate
	from this collaboration is forodesine. We have obtained worldwide exclusive rights to develop and ultimately distribute it, or
	any other, product candidates that might arise from research on these inhibitors. We have the option to expand our license agreement
	with the Licensors to include other inventions in the field made by the investigators or employees of the Licensors. We agreed
	to use commercially reasonable efforts to develop these drugs. In addition, we have agreed to pay certain milestone payments for
	each licensed product (which range in the aggregate from $1.4 million to almost $4.0 million&nbsp;per indication) for future development
	of these inhibitors, single digit royalties on net sales of any resulting product made by us, and to share approximately one quarter
	of future payments received from other third-party partners, if any. In addition, we have agreed to pay annual license fees, which
	can range from $150,000 to $500,000, that are creditable against actual royalties and other payments due to the Licensors. This
	agreement may be terminated by us at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach
	by the Licensors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In May 2010, we amended the license agreement through which we obtained
	worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series
	of PNP inhibitors, including forodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half
	in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to
	the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments we may receive in the future under our license
	agreement with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products,
	for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of
	any resulting product made by us remains unchanged. At our sole option and subject to certain agreed upon conditions, any future
	non-royalty payments due to be paid by us to the Licensors under the license agreement may be made either in cash, in shares of
	our common stock, or in a combination of cash and shares.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On November&nbsp;17, 2011, we further amended our agreements with
	the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined in the
	license agreement) received by us under our Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL. &nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	On June&nbsp;19, 2012, we further amended our agreements with the
	Licensors whereby the parties clarified the definition of the field with respect to PNP inhibition and the Licensors agreed to
	grant an exclusive worldwide license of BCX4430 to us for any antiviral use.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	The University of Alabama at Birmingham (&#8220;UAB&#8221;)
</U>
	.
</I>
	We currently have agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
	UAB performed specific research for us in return for research payments and license fees. UAB has granted us certain rights to any
	discoveries in these areas resulting from research developed by UAB or jointly developed with us. We have agreed to pay single
	digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. We
	have completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable
	for five-year terms throughout the life of the last patent and are terminable by us upon three months&#8217; notice and by UAB
	under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential
	information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed
	products. There is currently no activity between us and UAB on these agreements, but when we license this technology, such as in
	the case of the Shionogi and Green Cross agreements, or commercialize products related to these programs, we will owe sublicense
	fees or royalties on amounts it receives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Government Contracts
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
<I>
<U>
	U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;)
</U>
	.
</I>
	In January 2007, BARDA/HHS awarded us a $102.6 million four-year contract for the advanced development
	of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery
	and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend
	the i.v. peramivir program and to increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had
	awarded us a $55.0 million contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for
	the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS
	to $234.8 million and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S.
	In December 2013, we submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS
	contract expired on June 30, 2014 according to its terms.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Under the defined scope of work in the contract with BARDA/HHS for
	the development of peramivir, a process was undertaken to validate a U.S.-based manufacturer and the related method for producing
	commercial batches of peramivir active pharmaceutical ingredient (&#8220;API&#8221;). As a required outcome of this validation
	process, large quantities of peramivir API were produced. In accordance with our accounting practices, we recorded all costs associated
	with this validation process as research and development expenses in our Consolidated Statements of Comprehensive Loss. Simultaneously,
	revenue from the BARDA/HHS contract was also recorded in our Consolidated Statements of Comprehensive Loss in 2009. BARDA/HHS subsequently
	reimbursed us for these costs and upon reimbursement from BARDA/HHS, the associated peramivir API became property of the U.S.&nbsp;Government.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Under the terms of the contract, if we determine the amount of peramivir
	API produced under the contract is in excess of what is necessary to complete the contract, we can acquire any excess peramivir
	API at cost to use for our own purposes. We believe that as a result of the manufacturing campaign described above, more peramivir
	API has been produced than what was required to support U.S.&nbsp;regulatory approval. If we use any excess API for our other contracts
	or activities, we will need to reconcile through an appropriate acquisition process with BARDA/HHS and to determine the appropriate
	acquisition process remuneration for this API.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	On March 31, 2015, we announced that BARDA/HHS awarded us a contract
	for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
	BARDA/HHS contract includes a base contract of $13.3 million to support BCX4430 drug manufacturing, as well as $22.9 million in
	additional development options that can be exercised by the government, bringing the potential value of the contract to $36.2 million.
	As of December 31, 2015, a total of $16.3 million has been awarded under exercised options within this contract.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
<I>
<U>
	National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;)
</U>
	.
</I>
	In September 2013, NIAID/HHS contracted with us for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS,
	part of the National Institutes of Health, made an initial award of $5.0 million to the Company. The total funding under this contract
	as of December 31, 2015 could be up to $34.0 million, if all contract options are exercised by NIAID/HHS, over a five year period.
	The goals of this contract, including amendments, are to file IND applications for i.v. and i.m. BCX4430 for the treatment of Marburg
	virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial.
	As of December 31, 2015, a total of $29.9 million has been awarded under exercised options within this contract. BCX4430 is the
	lead compound in our BSAV research program.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
	contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
	that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments
	of progress and the continuation of the contract is based on our performance, the timeliness and quality of deliverables, and other
	factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
	by the government at any time for breach or without cause.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Patents and Proprietary Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Our success will depend in part on our ability to obtain and enforce
	patent protection for our products, methods, processes and other proprietary technologies, preserve our trade secrets, and operate
	without infringing on the proprietary rights of other parties, both in the United States and in other countries. We own or have
	rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate
	to compounds we are developing. We actively seek, when appropriate, protection for our products, proprietary technology and proprietary
	information by means of U.S.&nbsp;and foreign patents, trademarks and contractual arrangements. In addition, we rely upon trade
	secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology and products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	The patent positions of companies like ours are generally uncertain
	and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for our technology
	will depend on our success in obtaining effective patent claims and enforcing those claims once granted. We do not know whether
	any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our issued
	patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated, rendered unenforceable
	or circumvented, which could limit our ability to stop competitors from marketing related products or the length of term of patent
	protection that we may have for our products. In addition, the rights granted under any issued patents may not provide us with
	competitive advantages against competitors with similar compounds or technology. Furthermore, our competitors may independently
	develop similar technologies or duplicate any technology developed by us in a manner that does not infringe our patents or other
	intellectual property. Because of the extensive time required for development, testing and regulatory review of a potential product,
	it is possible that, before any of our product candidates or those developed by our partners can be commercialized, any related
	patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the
	patent.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, we have been issued approximately
	13 U.S.&nbsp;patents that expire between 2017 and 2030 and that relate to our HAE program compounds, neuraminidase inhibitor compounds
	and PNP compounds. We have licensed a number of compounds protected by certain composition of matter patents from AECOM and IRL,
	plus additional manufacturing patents, totaling 14 additional U.S. patents that expire between 2017 and 2029. Additionally, we
	have approximately 12 Patent Cooperation Treaty or U.S.&nbsp;patent applications pending related to HAE program compounds, neuraminidase
	inhibitor compounds, BSAV and PNP compounds. Our pending applications may not result in issued patents, our patents may not cover
	the products of interest or may not be enforceable in all, or any jurisdictions and our patents may not provide us with sufficient
	protection against competitive products or otherwise be commercially viable. After expiration of composition of matter patents
	for our products and product candidates, we may rely on data exclusivity, or in some cases, method of use patents. The enforceability
	of these patents varies from jurisdiction to jurisdiction and may not be allowed or enforceable in some territories where we may
	seek approval. We may not have the funds to continue patent prosecution or to defend all of our existing patents in our current
	patent estate and may selectively abandon patents or patent families worldwide or in certain territories.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Our success is also dependent upon the skills, knowledge and experience
	of our scientific and technical personnel, none of which is patentable. To help protect our rights, we require all employees, consultants,
	advisors and partners to enter into confidentiality agreements, which prohibit the disclosure of confidential information to anyone
	outside of BioCryst and, where possible, require disclosure and assignment to us of their ideas, developments, discoveries and
	inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information
	in the event of any unauthorized use or disclosure or the lawful development by others of such information.
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	The pharmaceutical and biotechnology industries are intensely competitive.
	Many companies, including biotechnology, chemical and pharmaceutical companies, are actively engaged in activities similar to ours,
	including research and development of drugs for the treatment of rare medical conditions. Many of these companies have substantially
	greater financial and other resources, larger research and development staffs, and more extensive marketing and manufacturing organizations
	than we do. In addition, some of them have considerable experience in preclinical testing, clinical trials and other regulatory
	approval procedures. In addition, there are also academic institutions, governmental agencies and other research organizations
	that are conducting research in areas in which we are working. We expect to encounter significant competition for any of the pharmaceutical
	products we plan to develop. Companies that successfully complete clinical trials, obtain required regulatory approvals and commence
	commercial sales of their products may achieve a significant competitive advantage.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
<I>
<U>
	Antivirals
</U>
	:
</I>
	The pharmaceutical market for products that prevent or treat influenza is very competitive. Key competitive
	factors for RAPIVAB (peramivir injection) include, among others, efficacy, ease of use, safety, price and cost-effectiveness, storage
	and handling requirements and reimbursement. A number of neuraminidase inhibitors are currently available in the U.S.&nbsp;and/or
	other counties, including Japan, for the prevention or treatment of influenza, including seasonal flu vaccines and F. Hoffmann-La
	Roche Ltd.&rsquo;s (&ldquo;Roche&rdquo;) TAMIFLU
<SUP>
	&reg;
</SUP>
	, GlaxoSmithKline plc&rsquo;s (&ldquo;GSK&rdquo;) RELENZA
<SUP>
	&reg;
</SUP>
	and Daiichi Sankyo Co., Ltd.&rsquo;s INAVIR
<SUP>
	&reg;
</SUP>
	. In addition, FUJIFILM Corporation&rsquo;s favipiravir, a polymerase
	inhibitor, is approved in Japan. Roche&rsquo;s neuraminidase inhibitor is also approved for prophylaxis of influenza, and both
	Roche and GSK have i.v. formulations in clinical trial development.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In January 2011, GSK announced initiation of a multi-country Phase
	3 study of i.v. zanamivir (the same active ingredient as in RELENZA) in hospitalized patients with influenza. The GSK study was
	completed during the 2014-2015 flu season. In addition to these companies with neuraminidase inhibitors, there are other companies
	working to develop additional antiviral drugs to be used against various strains of influenza. Currently, there are a number of
	other companies developing potential new influenza therapies. Various government entities throughout the world are offering incentives,
	grants and contracts to encourage additional investment into preventative and therapeutic agents against influenza, which may have
	the effect of further increasing the number of our competitors and/or providing advantages to certain competitors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	BCX4430 is a product candidate in our BSAV research program and
	is currently being developed under a contract with NIAID/HHS. The objective of our BSAV program is to develop BCX4430 as a broad-spectrum
	therapeutic for viruses that pose a threat to national health and security. The U.S. Government is investing in a number of programs
	intended to address gaps in its medical countermeasure plan. Due to the Ebola outbreak in West Africa in 2014, investment in medical
	countermeasures has increased worldwide. Therapeutic products with potentially promising data to treat Ebola include FUJIFILM Corporation&rsquo;s
	favipiravir (polymerase inhibitor), Tekmira Pharmaceuticals Corporation&rsquo;s TKM-Ebola (RNAi interference based) and Mapp Biopharmaceutical,
	Inc.&rsquo;s ZMapp (antibody-based). Both TKM-Ebola and ZMapp have been used in Ebola patients. Gilead Sciences, Inc announced
	in October 2015 that it had provided the investigational compound, GS-5734, to two patients with Ebola for compassionate use.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
<U>
	HAE
</U>
	:
</I>
	HAE is an autosomal dominant disease characterized
	by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and the
	larynx. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attacks, life-threatening. Prevalence for
	HAE is uncertain but is estimated to be approximately 1 case per 50,000 persons without known differences among ethnic groups and
	is caused by deficient (Type I) or dysfunctional (Type II) levels of C1-Inhibitor (&#8220;C1-INH&#8221;), a naturally occurring
	molecule that is known to inhibit kallikrein, bradykinin, and other serine proteases in the blood. If left untreated, HAE can result
	in a mortality rate as high as 40% primarily due to upper airway obstruction. There are a number of licensed and developmental
	therapies for HAE, including the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	C1-INH therapy is available as an acute therapy (Berinert
<SUP>
	&#174;
</SUP>
	) and as a prophylactic therapy (Cinryze
<SUP>
	&#174;
</SUP>
	). These therapies are available intravenously and work by replacing the missing or malfunctioning C1-INH protein in patients.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<P STYLE="MARGIN: 0PT 0">
	Kallikrein Inhibition
<B>
	-
</B>
	Kalbitor
<SUP>
	&reg;
</SUP>
	(ecallantide)
	is a specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously
	in an inpatient setting.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Bradykinin receptor antagonist
<B>
	-
</B>
	Firazyr
<SUP>
	&#174;
</SUP>
	(icatibant) is a competitive antagonist of the bradykinin B2 receptor. Firazyr is approved for the treatment of acute attacks and is administered by subcutaneous administration.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Other medications - Prophylactic administration of synthetic attenuated androgens (generically available as danazol or stanozolol) has been utilized to reduce the frequency or severity of attacks. However, long-term use of danazol or stanozolol may result in virilization and arterial hypertension. Six-month liver function tests, annual lipid profiles, and biennial hepatic ultrasound are recommended because these medications increase production of C1-INH in the liver.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In addition to avoralstat, BCX7353 and our other second generation
	compounds, there are a number of other HAE therapies in development. These include a prophylactic plasma derived C1-INH delivered
	by subcutaneous injection in Phase 3 (CSL Behring); DX-2930/SHP643, a monoclonal antibody administered by subcutaneous injection
	for prophylactic treatment of HAE in Phase 3 (Shire PLC); ISIS-PKK, a RNA-targeted antisense drug to inhibit prekallikrein for
	prophylactic treatment of HAE in Phase 1 (ISIS Pharmaceuticals, Inc.); and two potential oral kallikrein inhibitors being developed
	by KalVista and Global Blood Therapeutics, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In order to compete successfully in these and other therapeutic
	areas, we must develop proprietary positions in patented drugs for therapeutic markets that have not been satisfactorily addressed
	by conventional research strategies and, in the process, expand our expertise in structure-based drug design. Our product candidates,
	even if successfully tested and developed, may not be adopted by physicians over other products and may not offer economically
	feasible alternatives to other therapies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Research and Development
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We initiated our research and development activities in 1986. We have
	assembled a scientific research staff with expertise in a broad base of advanced research technologies including protein biochemistry,
	X-ray crystallography, chemistry and pharmacology. Our research facilities, located in Birmingham, Alabama, include protein biochemistry
	and organic synthesis laboratories, testing facilities, X-ray crystallography, computer and graphics equipment and facilities to
	make product candidates on a small scale for early stage clinical trials. During the years ended December 31, 2015, 2014 and 2013,
	our research and development expenses were $72.8 million, $51.8 million and $41.9 million, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Compliance
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We conduct our business in an ethical, fair, honest and lawful manner.
	We act responsibly, respectfully and with integrity in our relationships with patients, health care professionals, collaborators,
	governments, regulatory entities, stockholders, suppliers and vendors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In order to ensure compliance with applicable laws and regulations,
	our Chief Financial Officer, General Counsel and Vice President of Human Resources oversee compliance training, education, auditing
	and monitoring; enforce disciplinary guidelines for any infractions of our corporate polices; implement new policies and procedures;
	respond to any detected issues; and undertake corrective action procedures. Our controls address compliance with laws and regulations
	that govern public pharmaceutical companies including, but not limited to, the following: federal and state law, such as the Sarbanes-Oxley
	Act of 2002 and the U.S. Foreign Corrupt Practices Act of 1977; NASDAQ listing requirements; the regulations of the Financial Industry
	Regulatory Authority; the Securities and Exchange Commission (&ldquo;SEC&rdquo;); the FDA; and the United States Department of
	Health and Human Services. Our standard operating procedures are designed to provide a framework for corporate governance in accordance
	with ethical standards and best legal practices.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Government Regulation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The FDA regulates the pharmaceutical and biotechnology industries
	in the U.S., and our product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
	The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage,
	approval, advertising, promotion, sale and distribution of pharmaceutical products. In foreign countries, our products are also
	subject to extensive regulation by foreign governments. These government regulations will be a significant factor in the production
	and marketing of any pharmaceutical products that we develop. Failure to comply with applicable FDA and other regulatory requirements
	at any stage during the regulatory process may subject us to sanctions, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	delays;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	warning letters;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fines;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	product recalls or seizures;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	injunctions;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	penalties;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	refusal of the FDA to review pending market approval applications or supplements to approval applications;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	total or partial suspension of production;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	civil penalties;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	withdrawals of previously approved marketing applications;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	criminal prosecutions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The regulatory review and approval process is lengthy, expensive
	and uncertain. Before obtaining regulatory approvals for the commercial sale of any products, we or our partners must demonstrate
	that our product candidates are safe and effective for use in humans. The approval process takes many years, substantial expenses
	may be incurred and significant time may be devoted to clinical development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Before testing potential product candidates in humans, we carry
	out laboratory and animal studies to determine safety and biological activity. After completing preclinical trials, we must file
	an IND, including a proposal to begin clinical trials, with the FDA. Thirty days after filing an IND, a Phase 1 human clinical
	trial can start, unless the FDA places a hold on the trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Clinical trials to support a NDA are typically conducted in three
	sequential phases, but the phases may overlap.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Phase 1&#8212;During Phase 1, the initial introduction of the drug
	into healthy volunteers, the drug is tested to assess metabolism, pharmacokinetics and pharmacological actions and safety, including
	side effects associated with increasing doses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Phase 2&#8212;Phase 2 usually involves trials in a limited patient
	population to: (1)&nbsp;assess the efficacy of the drug in specific, targeted indications; (2)&nbsp;assess dosage tolerance and
	optimal dosage; and (3)&nbsp;identify possible adverse effects and safety risks.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Phase 3 (pivotal) &#8212;If a compound is found to be potentially
	effective and to have an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials, also called pivotal studies,
	major studies or advanced clinical trials, are undertaken to further demonstrate clinical efficacy and to further test for safety
	within an expanded patient population at geographically dispersed clinical trial sites. In general, the FDA requires that at least
	two adequate and well-controlled Phase 3 clinical trials be conducted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Initiation and completion of the clinical trial phases are dependent
	on several factors including things that are beyond our control. For example, the clinical trials cannot begin at a particular
	site until that site receives approval from its Institutional Review Board (&#8220;IRB&#8221;), which reviews the protocol and
	related documents. This process can take from several weeks to several months. In addition, clinical trials are dependent on patient
	enrollment, but the rate at which patients enroll in the study depends on:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	willingness of investigators to participate in a study;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	ability of clinical sites to obtain approval from their IRB;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the availability of the required number of eligible subjects to be enrolled in a given trial;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the availability of existing or other experimental drugs for the disease we intend to treat;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the willingness of patients to participate;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the patients meeting the eligibility criteria.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Delays in planned patient enrollment may result in increased expense
	and longer development timelines.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	After successful completion of the required clinical testing, generally
	an NDA is submitted. Upon receipt of the NDA, the FDA will review the application for completeness. Within 60 days, the FDA will
	determine if the application is sufficiently complete to warrant full review and will consider the application &#8220;filed&#8221;
	at that time. Also upon receipt of the application, the FDA will assign a review priority to the application. Priority review applications
	are usually reviewed within 8 months; standard review applications are usually reviewed within 12 months. The FDA will usually
	refer NDAs for new molecular entities to an appropriate advisory committee for review and evaluation in regards to providing a
	recommendation as to whether the application should be approved. The FDA is not bound to follow the recommendation of an advisory
	committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Following the review of the application, which may include requests
	for additional information from the sponsor and&nbsp;results from inspections of manufacturing and clinical sites, the FDA will
	issue an &#8220;action letter&#8221; on the application. The action letter will either be an &#8220;approval letter,&#8221; in
	which case the product may be lawfully marketed in the United States, or a &#8220;complete response letter.&#8221; A complete response
	letter will state that the FDA cannot approve the NDA in its present form and, usually, will describe all of the specific deficiencies
	that the FDA has identified in the application. The complete response letter, when possible, will include the FDA&#8217;s recommended
	actions to place the application in a condition for approval. Deficiencies can be minor (e.g., labeling changes) or major (e.g.,
	requiring additional clinical trials). A complete response letter may also be issued before the FDA conducts the required facility
	inspection and/or reviews labeling, leaving the possibility that additional deficiencies in the original NDA could be subsequently
	cited. An applicant receiving a complete response letter is permitted to resubmit the NDA addressing the identified deficiencies
	(in which case a new two or six month review cycle will begin), or withdraw the NDA. The FDA may consider a failure to take action
	within one year of a complete response letter to be a request to withdraw, unless the applicant has requested an extension of time
	in which to resubmit. If the FDA approves an NDA, the marketing of the product will be limited to the particular disease states
	and conditions of use that are described in the product label.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We and all of our contract manufacturers are also required to comply
	with the applicable FDA current Good Manufacturing Practice, or cGMP, regulations during clinical development and to ensure that
	the product can be consistently manufactured to meet the specifications submitted in an NDA. The cGMP regulations include requirements
	relating to product quality as well as the corresponding maintenance of records and documentation. Manufacturing facilities must
	be approved by the FDA before they can be used to manufacture our products. Based on an inspection, the FDA determines whether
	manufacturing facilities are in compliance with applicable regulations. Manufacturing facilities in non-United States countries
	that are utilized to manufacture drugs for distribution into the United States are also subject to inspection by the FDA. Additionally,
	failure to comply with local regulatory requirements could affect production and availability of product in relevant markets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Human Resources
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	As of January&nbsp;31, 2016, we had approximately 70&nbsp;employees,
	of whom approximately 50 were engaged in the research and development function of our operations. Our research and development
	staff, 24 of whom hold Ph.D. or M.D. degrees, have diversified experience in biochemistry, pharmacology, X-ray crystallography,
	synthetic organic chemistry, computational chemistry, medicinal chemistry, clinical development and regulatory affairs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Our employees are not represented by any collective bargaining agreements,
	and we have never experienced a work stoppage. Employees are required to execute confidentiality and assignment of intellectual
	property agreements. We consider our relations with our employees to be satisfactory.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Available Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	We have available a website on the Internet. Our address is www.biocryst.com.
	We make available, free of charge, at our website our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current
	Reports on Form&nbsp;8-K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
	Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. We also make
	available at our website copies of our audit committee charter, compensation committee charter, corporate governance and nominating
	committee charter and our code of business conduct, which applies to all our employees as well as the members of our Board of Directors.
	Any amendment to, or waiver from, our code of business conduct will be posted on our website.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Financial Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	For information related to our revenues, profits, net loss and total
	assets, in addition to other financial information, please refer to the Financial Statements and Notes to Financial Statements
	contained in this Annual Report. Financial information about revenues derived from foreign countries is included in Note&nbsp;1
	to the Financial Statements contained in this Annual Report.
</P>
</EFX_BUSINESS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_022616P_HTM_A_002">
</A>
	ITEM 1A.
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
	An investment in our stock involves risks. You should carefully
	read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial
	condition or results of operations, along with all of the other information included in our other filings with the Securities and
	Exchange Commission, before deciding to buy our common stock.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Risks Relating to Our Business
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We have incurred losses since our inception, expect to continue to incur
	such losses, and may never be profitable.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Since our inception, we have not achieved sustained profitability.
	We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
	efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	To become profitable, we, or our collaborative partners, must successfully
	manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
	agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
	license agreements or revenues directly from product sales.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Because of the numerous risks and uncertainties associated with developing
	our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
	if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
	unable to achieve and sustain profitability, the market value of our common stock will likely decline.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Our success depends upon our ability to advance our products through
	the various stages of development, especially through the clinical trial process.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	To receive the regulatory approvals necessary for the sale of our
	product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
	is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
	duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
	in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
	commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, avoralstat,
	BCX7353 and our other rare disease product candidates), even after earlier clinical trials show promising results. The development
	of our product candidates, including our clinical trials, may not be adequately designed or executed, which could affect the potential
	outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. The pre-clinical
	and clinical data from our product candidates could cause us or regulatory authorities to interrupt, delay, modify or halt preclinical
	or clinical trials of a product candidate. Undesirable or inconclusive data or side effects in humans could also result in the
	FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted indications. In addition, the
	FDA or other regulatory agencies may determine that study data from our product candidates necessitates additional studies or study
	designs which differ from our planned development strategy, and regulatory agencies may also require patient monitoring and testing
	or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost
	and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate
	clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail
	to demonstrate that our product candidates are safe or effective and have acceptable commercial viability. Regulatory authorities
	may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our ability to successfully complete clinical trials is dependent
	upon many factors, including but not limited to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to find suitable clinical sites and investigators to enroll patients;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the ability to maintain contact with patients to provide complete data after treatment;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our product candidates may not prove to be either safe or effective;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	clinical protocols or study procedures may not be adequately designed or followed by the investigators;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	manufacturing or quality control problems could affect the supply of product candidates for our trials; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements by governmental agencies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Clinical trials are lengthy and expensive. We or our partners incur
	substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that
	the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies
	of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment can result in increased
	costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates,
	we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval
	for the product candidates.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We focus on rare diseases, which may create additional risks and challenges.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Because we focus on developing drugs as treatments for rare diseases,
	we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
	equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
	to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
	designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
	provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance
	on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful
	in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead
	to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will
	receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors
	may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product
	candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We have received orphan and fast track designations for avoralstat
	in the United States. Despite this designation; we may not experience a faster development, review or approval process compared
	to the conventional FDA procedures. The FDA may withdraw fast track designation if it believes the designation is no longer supported
	by data from our clinical development program. Although we have also received Sakigake designation for BCX7353 in Japan, we may
	not experience a faster development, review or approval process compared to the conventional process.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Our clinical trials may not adequately show that our product candidates
	are safe or effective.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Progression of our product candidates through the clinical development
	process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being
	treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve
	any of these endpoints in any of our programs, including avoralstat, BCX7353 and our other rare disease product candidates, could
	result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development
	of our product candidates and could result in significant unexpected costs or the termination of programs.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If our development collaborations with third parties, such as our development
	partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We rely heavily upon third parties for many important stages of our
	product candidate development, including but not limited to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	licensing or designing of enzyme inhibitors for development as product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	execution of certain preclinical studies and late-stage development for our compounds and product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	management of our clinical trials, including medical monitoring and data management;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	execution of additional toxicology studies that may be required to obtain approval for our product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	formulation improvement strategies and methods, including those for avoralstat; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our failure to engage in successful collaborations at any one of these
	stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
	other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
	organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
	materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
	their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
	both the development of our product candidates and the availability of any potential commercial product.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If we lose our relationship with any one or more of these parties,
	we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
	We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
	is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
	as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
	(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
	and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
	if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
	could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could
	be materially adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Because we have limited manufacturing experience, we depend on third-party
	manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
	in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
	manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We have limited manufacturing experience and only a small scale manufacturing
	facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our
	product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party
	manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party
	manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting
	our requirements including but not limited to problems involving:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	inconsistent production yields;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	product liability claims or recalls of commercial product;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	difficulties in scaling production to commercial and validation sizes;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	interruption of the delivery of materials required for the manufacturing process;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	scheduling of plant time with other vendors or unexpected equipment failure;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	potential catastrophes that could strike their facilities or have an effect on infrastructure;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	poor quality control and assurance or inadequate process controls; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for avoralstat, BCX7353 and BCX4430.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	These contract manufacturers may not be able to manufacture
	the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also
	have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline
	to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue
	to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is
	manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s
	cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of
	a product. The FDA or similar foreign regulatory agencies may at any time implement new standards, or change their interpretation
	and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are
	unable to comply, we or they may be subject to regulatory action, civil actions or penalties any of which could be costly to the
	Company and could result in a delay or shortage of product.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If we are unable to maintain current manufacturing or other contract
	relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
	manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
	we may not be able to complete development of, seek timely approval of, or market, our product candidates.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our raw materials, drug substances, and product candidates are manufactured
	by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items,
	this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We face intense competition, and if we are unable to compete effectively,
	the demand for our products, if any, may be reduced.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The biotechnology and pharmaceutical industries are highly competitive
	and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
	that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
	pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
	we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
	organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
	FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
	product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
	commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
	exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
	of potential product candidates for desirable disease targets licensing of desirable product candidates, and development and marketing
	of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
	companies. Competition may also arise from, among other things:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	other drug development technologies;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	new small molecule or other classes of therapeutic agents.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Developments by others may render our product candidates
	or technologies obsolete or noncompetitive.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We and our partners are performing research on or developing products for the treatment of several disorders
	including HAE and recurrent/refractory peripheral T-cell lymphoma, as well as broad spectrum antivirals that may be developed as
	medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical products we plan to develop.
	Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and
	commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive
	advantage. Such is the case with Eisai Co. Ltd.&rsquo;s TARGRETIN
<SUP>
	&reg;
</SUP>
	for cutaneous T-lymphoma; the current neuraminidase
	inhibitors marketed by GSK and Roche for influenza; CINRYZE
<SUP>
	&reg;
</SUP>
	, KALBITOR
<SUP>
	&reg;
</SUP>
	and FIRAZYR
<SUP>
	&reg;
</SUP>
	,
	marketed by Shire Pharmaceuticals, Inc. for HAE; and BERINERT
<SUP>
	&reg;
</SUP>
	, marketed by CSL for HAE. Therapeutic products with
	potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&rsquo;s ZMapp (antibody-based) and Gilead Sciences,
	Inc.&rsquo;s product currently under development (small molecule), both of which have been used in Ebola infected patients. Further,
	several pharmaceutical and biotechnology firms, including major pharmaceutical companies and specialized structure-based drug design
	companies, have announced efforts in the field of structure-based drug design and molecules in development in the fields of HAE
	and in other therapeutic areas where we have discovery and development efforts ongoing. If one or more of our competitors&rsquo;
	products or programs are successful, the market for our products may be reduced or eliminated.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Compared to us, many of our competitors and potential competitors
	have substantially greater:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	capital resources;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	research and development resources, including personnel and technology;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	regulatory experience;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	preclinical study and clinical testing experience;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	manufacturing and marketing experience;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	production facilities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Any of these competitive factors could impede our funding efforts,
	render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We face risks related to our government-funded programs; if BARDA/HHS
	or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the
	programs associated with such funding and could have a significant negative impact on our revenues and cash flows.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our projections of revenues and incoming cash flows are substantially
	dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were
	to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional
	funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development
	effort.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
	U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
	may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government
	terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract
	schedule and terms, significant negative impact on our cash flows and operations could result.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
	requirements, which create additional risks of reduction or loss of funding.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We have completed work under a contract with BARDA/HHS for
	the development of our neuraminidase inhibitor, peramivir. We also have entered into contracts with BARDA/HHS and NIAID/HHS for
	the development of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus
	disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including
	general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found
	to be in violation, could result in contract termination. &nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	U.S. Government contracts typically contain a number of extraordinary
	provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to
	us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government
	to unilaterally:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	terminate or reduce the scope of our contract with or without cause;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	interpret relevant regulations (federal acquisition regulation clauses);
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	require performance under circumstances which may not be favorable to us;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	require an in process review where the U.S. Government will review the project and its options under the contract;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	control the timing and amount funding, which impacts the development progress of our programs; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	audit and object to our contract-related costs and fees, including allocated indirect costs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Our government contracts with BARDA/HHS and NIAID/HHS have termination
	and audit provisions which create additional risks to us.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The U.S. Government may terminate its contracts with us either for
	its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
	provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
	completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
	or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
	under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
	under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
	if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
	with the contract schedule and terms, significant negative impact on our cash flows and operations could result.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	As a U.S. Government contractor, we are required to comply with applicable
	laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of
	any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems
	and policies, including those relating to our purchasing, property, estimating, compensation and management information systems.
	Audits conducted by the U.S. Government for the completed BARDA/HHS contract have been performed and concluded through fiscal 2009;
	all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS contracts may occur at
	the election of the U.S. Government and have been concluded through fiscal 2013. Based on the results of its audits, the U.S. Government
	may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of
	revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event
	BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate
	was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a
	result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties
	and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and
	suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if
	allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may
	not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk
	of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
	to private sector commercial companies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If we fail to reach milestones or to make annual minimum payments or
	otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
	remedies.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If we are unable or fail to meet payment obligations, performance
	milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
	development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in
	accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors
	may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
	or commercialization of the product would cease.&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If we fail to obtain additional financing or acceptable partnership
	arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	As our programs advance, our costs are likely to increase. Our current
	and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval
	process requirements, and the additional personnel resources and testing required for supporting the development of our product
	candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
	depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
	for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships
	with third parties for the development of our product candidates, including avoralstat, BCX7353 and our other rare disease product
	candidates; the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for RAPIVAB
	or BCX4430 by any government agency or other party; the progress and results of our current and proposed clinical trials for our
	most advanced product candidates, including avoralstat, BCX7353 and our other rare disease product candidates; the progress made
	in the manufacture of our lead products and the progression of our other programs.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We expect that we will be required to raise additional capital to
	complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
	Additional funding, whether through additional sales of securities or collaborative arrangements with partners, including governmental
	agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when needed or on terms acceptable
	to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable
	than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or
	rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights
	to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate
	certain of our research and development programs.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	In order to continue future operations and continue our drug development
	programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government
	funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise
	additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development
	programs, including post approval studies for RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;the avoralstat
	development program (including, but not limited to, formulation trials, phase 3 trials, long-term human safety studies, and the
	timing of carcinogenicity studies), the progress of BCX7353 and our other rare disease product candidates, funding for and continued
	successful development of BCX4430, and the progress of our early discovery programs. In addition, constriction and volatility in
	the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure
	to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners
	(which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current
	economic and political environment. Any such instability may impact these parties&rsquo; ability to fulfill contractual obligations
	to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers
	may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place
	severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit
	markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a
	material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product
	candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If we fail to successfully commercialize or establish collaborative
	relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations
	under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our business strategy is to increase the asset value of our product
	candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
	third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development,
	regulatory approval, marketing, sales and distribution of our product candidates.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Currently, we have established collaborative relationships with Mundipharma
	for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
	of peramivir, in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK
	Limited for RAPIVAB in the United States and countries other than Israel, Japan, Korea and Taiwan. The process of establishing
	and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our contracts for collaborative arrangements may expire;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our partners may choose to pursue alternative technologies, including those of our competitors;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we may have disputes with a partner that could lead to litigation or arbitration;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we do not have day to day control over the activities of our partners and have limited control over their decisions;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we or our partners may not devote sufficient capital or resources towards our product candidates; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we or our partners may not comply with applicable government regulatory requirements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If we or our partners fail to fulfill our responsibilities in a timely
	manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may
	be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If
	we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further
	development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative
	sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business,
	because if our product candidates do not progress through the development process or reach the market in a timely manner, or at
	all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We do not have a great deal of experience in commercializing our products
	or technologies, and our future revenue generation is uncertain.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We do not have a great deal of experience in commercializing our
	products or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force
	and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products
	we currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status
	of our preclinical and clinical programs. If we fail to advance these programs to the point of being able to enter into successful
	collaborations, we will not receive any potential future event or other collaborative payments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our ability to receive revenue from products we commercialize presents
	several risks, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	reimbursement is constantly changing, which could greatly affect usage of our products; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Commercialization of RAPIVAB by our partners
	is subject to the potential commercialization risks described herein and numerous additional risks. Any potential revenue benefits
	to us in the form of milestone payments, royalties or other consideration are highly speculative.
</I>
</B>
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Commercialization success of RAPIVAB is uncertain and is subject to
	all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
	commercialization of RAPIVAB is subject to further risks and may be negatively impacted by a number of factors, including, but
	not limited to, the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	necessary funding for post-marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB to our partners and may result in little to no milestones or royalties to us;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	effectiveness of marketing efforts for RAPIVAB by our partners;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	market satisfaction with existing alternative therapies;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	perceived efficacy relative to other available therapies;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	disease prevalence;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	cost of treatment;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	pricing and availability of alternative products;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	marketing and sales activities of competitors;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	shifts in the medical community to new treatment paradigms or standards of care; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	relative convenience and ease of administration.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We are subject to various federal and state laws related to RAPIVAB
	and other products under development and, if we or our partners do not comply with these regulations, we could face substantial
	penalties.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our or our partners activities related to RAPIVAB, or any of our
	other products under development and following their regulatory approval, are subject to regulatory and law enforcement
	authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local
	governments. In the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and
	commercialization efforts, we continue to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For
	example, we are responsible for reporting adverse drug experiences, we have responsibility for certain post-approval studies,
	we may have responsibilities and costs related to a recall or withdrawal of RAPIVAB from sale, we may incur liability
	associated with RAPIVAB manufacturing contracted by us or in support of any of our partners, we are required to maintain
	records and provide data and reports to regulatory agencies related to RAPIVAB (e.g. risk evaluation and mitigation
	strategies, track and trace requirements, adverse events), and we may incur certain promotional regulatory and government
	pricing risks, all of which could have a material adverse impact on our operations and financial condition. In addition, we
	are now subject to the federal physician sunshine act and certain similar legislation in various states. We are subject to
	various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal and state
	anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our
	distributors, might be challenged under anti-kickback or similar laws. Violations of the physician sunshine act and similar
	state legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and
	civil monetary penalties, and future exclusion from participation in government healthcare programs.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We have a number of outstanding post-marketing commitments to the
	FDA that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons,
	including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators
	or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study
	of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial,
	we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing
	this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be
	subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject
	to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies.
	Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to
	the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the
	approval of RAPIVAB and any other future product candidates may be subject to requirements for costly post-marketing testing and
	surveillance to monitor its safety or efficacy.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Advertising and promotion are subject to stringent FDA rules and oversight
	and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
	in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
	with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
	safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the
	NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In addition, the research, manufacturing, distribution, sale and promotion
	of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
	the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
	of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
	successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
	and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
	and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
	Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
	subject to federal and state consumer protection and unfair competition laws.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If our operations with respect to RAPIVAB or our other products that
	are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described
	above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
	damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring
	of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs
	can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any
	action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
	expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance
	with all applicable federal and state fraud and abuse laws may be costly.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We and our partners may be subject to
	new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and
	adversely affect our or our partners ability to market our products, including RAPIVAB, obtain collaborators and raise
	capital.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Patient Protection and Affordable Care Act, or PPACA, made extensive changes to the delivery of health
	care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies, some of which became effective immediately
	and others of which will be taking effect over the next several years. For example, the PPACA seeks to expand health care coverage
	to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA will also impose substantial
	costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must
	be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand
	prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of
	hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels
	for health care items and services generally, including pharmaceuticals. It also will require reporting and public disclosure of
	payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals. We cannot predict
	what effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business. Further,
	it remains unclear whether there will be any changes made to provisions of the PPACA or other health care laws through acts of
	Congress in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors
	of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical
	products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers will
	also be required to report and disclose investment interests held by physicians and their immediate family members during the preceding
	calendar year. &nbsp;Failure to submit required information may result in civil monetary penalties for payments, transfers of value
	or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar
	provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because
	of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could
	be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business,
	financial condition, results of operations and growth prospects.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In addition, there have been a number of other legislative and regulatory
	proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed
	at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable
	unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational
	expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face
	a material adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp; As a result of
	these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change
	our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of
	operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Managed care organizations are increasingly challenging the prices
	charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed
	care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement
	levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s
	patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months
	before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party
	payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product
	we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement
	on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial
	condition and results of operations. &nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	There are risks related to the potential government use or sale of peramivir
	(RAPIVAB).
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	United States Government use or sale of RAPIVAB in emergency situations,
	or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for
	influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be
	generally safe, well-tolerated and effective. Such government use of peramivir may create certain liabilities for us or our partners
	in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able to fully meet
	the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional orders
	of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or replace
	peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully
	enforce our intellectual property rights.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	There is no assurance that the non-U.S. partnerships that we have entered into for peramivir will result
	in any order for peramivir in those countries. There is no assurance that peramivir will be approved for any use or will achieve
	market approval in additional countries. In the event that any emergency use or market approval is granted, there is no assurance
	that any government order or commercialization of peramivir in any countries will be substantial or will be profitable to us. In
	addition, the sale of peramivir, emergency use or other use of peramivir in any country may create certain liabilities for us and
	our partners.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If we or our partners do not obtain and maintain governmental approvals
	for our product candidates under development, we or our partners will not be able to sell these potential products, which would
	significantly harm our business because we will receive no revenue.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We or our partners must obtain regulatory approval before marketing
	or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
	sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
	partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
	FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
	government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
	our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
	If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
	results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
	uses for a product candidate and/or may require post-approval studies.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The FDA regulates, among other things, the record keeping and storage
	of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
	data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
	significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
	damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
	whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
	are wide ranging and govern, among other things:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	adverse drug experience reporting regulations;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	product promotion;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	product manufacturing, including good manufacturing practice requirements;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	product changes or modifications.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our failure to comply with existing or future regulatory requirements,
	or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
	not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing. &nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Royalties and milestone payments from Shionogi under our license agreement
	with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
	its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
	under the PhaRMA Notes.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
	million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
	payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and,
	if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge
	arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest
	in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes
	until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated
	to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014,
	the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an
	event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be
	able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest
	in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture or other documents related to&nbsp;the
	PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following
	repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Because an event of default has occurred under the PhaRMA Notes, the
	holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the
	PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that
	might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Royalty Sub&#8217;s ability to service its payment obligations in
	respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks.
	Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
	of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
	product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
	to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
	PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
	our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
	related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
	accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We may be required to pay significant premiums under the foreign currency
	hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
	under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
	and cash flows attributable to the foreign currency hedge arrangement.&nbsp;
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In connection with the issuance by Royalty Sub of the PhaRMA Notes,
	we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese
	yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the
	amount of $2.0 million in each May continuing through May 2020. Such payment will be required if, in May of the relevant year,
	the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement)
	is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the
	currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results
	and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign
	currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a
	foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If we fail to adequately protect or enforce our intellectual property
	rights or secure rights to patents of others, the value of those rights would diminish.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our success will depend in part on our ability and the abilities of
	our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
	and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
	preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
	The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
	questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
	the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
	predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
	patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
	may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
	in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
	on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
	in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
	to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
	to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
	The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We also rely on trade secrets to protect technology in cases when
	we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
	the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
	ability to receive patent protection or protect our proprietary information may be imperiled.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We may be involved in lawsuits to protect or enforce our patents, the
	patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful
</I>
</B>
	.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Competitors may infringe or otherwise violate our patents, the patents
	of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
	file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
	could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
	patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
	products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
	are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
	infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
	that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
	cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
	we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
	or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
	available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
	the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
	which would give our competitors access to the same intellectual property.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If we or our partners are unable or fail to adequately initiate, protect,
	defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
	to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
	produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
	of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
	infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
	have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
	We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
	foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
	certain trademark and trade name applications worldwide. We cannot assure you as to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the degree and range of protection any patents will afford against competitors with similar products;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	if and when patents will issue;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	If the USPTO or other foreign patent office upholds patents
	issued to others or if the USPTO grants patent applications filed by others, we may have to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	obtain licenses or redesign our products or processes to avoid infringement;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	stop using the subject matter claimed in those patents;&nbsp;or
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	pay damages.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	We may initiate, or others may bring against us, litigation
	or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign
	patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application
	could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any
	such proceeding may be substantial whether or not we are successful.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our success is also dependent upon the skills, knowledge and experience,
	none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
	advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
	outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
	agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
	any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
	is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
	and any such events would significantly impair the value of such product candidates.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We face an inherent risk of liability in the event that the use or misuse
	of our products results in personal injury or death and our product liability insurance coverage may be insufficient.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If the use or misuse of peramivir or any other regulatory body-approved
	products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims
	brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
	candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We
	cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product
	candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense
	costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability
	that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity
	could be harmful to our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We face an inherent risk of product liability exposure related to
	the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
	of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials.
	Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
	insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
	effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
	causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
	against us, with or without merit, could result in:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	withdrawal of clinical trial volunteers or patients;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	damage to our reputation and the reputation of our products, resulting in lower sales;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	regulatory investigations that could require costly recalls or product modifications;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	litigation costs;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the diversion of management&#8217;s attention from managing our business.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Insurance coverage is increasingly more costly and difficult to obtain
	or maintain.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	While we currently have insurance for our business, property, directors
	and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to assume more
	risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required
	to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our
	insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on
	our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain
	or maintain insurance coverage at reasonable costs or at all.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If our facility incurs damage or power is lost for
	a significant length of time, or if we incur significant cost overruns or delays in the construction of our new research facility
	in Birmingham, Alabama,
<FONT STYLE="FONT-SIZE: 10PT">
	our business will suffer.
</FONT>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We store clinical and stability samples at our facility that could
	be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
	addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
	delays in our drug development process.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In addition, we store most of our preclinical and clinical data at
	our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer
	systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug
	development process and any system failure could harm our business and operations.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We also face the risk that the costs and time
	required in connection with the construction of our new research facility in Birmingham, Alabama could exceed our current expectations.
	If there is a significant cost overrun or significant delay in the completion of the construction, our business, financial condition,
	and results of operations could be adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	A significant disruption in our information technology systems or a
	cyber-security breach could adversely affect our business.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We are increasingly dependent on information technology systems to
	operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
	or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
	error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
	technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
	become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
	or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
	of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
	legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
	security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
	technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
	any such events could adversely affect our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If we fail to retain our existing key personnel or fail to attract and
	retain additional key personnel, the development of our product candidates and commercialization of our products and the related
	expansion of our business will be delayed or stopped.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We are highly dependent upon our senior management and scientific
	team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
	for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
	and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
	our business because we rely upon these personnel for many critical functions of our business.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	If because of our use of hazardous materials, we violate any environmental
	controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our research and development involves the controlled use of hazardous
	materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
	the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
	materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
	our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
	require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations. &nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Risks relating to investing in our common stock
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Our existing principal stockholders hold a substantial amount of our
	common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Several of our stockholders own greater than 5% of our outstanding
	common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations
	based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters
	requiring approval of the stockholders, including the election of our directors and other corporate actions.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Our stock price has been, and is likely to continue to be, highly volatile,
	which could result in the value of an investment in our common stock to decline significantly.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The market prices for securities of biotechnology companies in general
	have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently,
	and these fluctuations are often not related to our financial results. For the twelve months ended December 31, 2015, the 52-week
	range of the market price of our stock was from $7.85 to $16.83 per share. The following factors, in addition to other risk factors
	described in this section, may have a significant impact on the market price of our common stock:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	announcements of technological innovations or new products by us or our competitors;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	developments or disputes concerning patents or proprietary rights;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	additional dilution through sales of our common stock or other derivative securities;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	status of new or existing licensing or collaborative agreements and government contracts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	announcements relating to the status of our programs;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	developments and announcements regarding new and virulent strains of influenza;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	we or our partners achieving or failing to achieve development milestones;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	publicity regarding actual or potential medical results relating to products under development by us or our competitors;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	publicity regarding certain public health concerns for which we are or may be developing treatments;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	regulatory developments in both the United States and foreign countries;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	public concern as to the safety of pharmaceutical products;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	actual or anticipated fluctuations in our operating results;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; WIDTH: 95%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	changes in financial estimates or recommendations by securities analysts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	changes in the structure of healthcare payment systems, including developments in price control legislation;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	additions or departures of key personnel or members of our board of directors;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	economic and other external factors or other disasters or crises; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	period-to-period fluctuations in our financial results.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Future sales and issuances of securities may dilute the ownership interests
	of our current stockholders and cause our stock price to decline.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Future sales of our common stock by current stockholders into the
	public market could cause the market price of our stock to fall. As of January&nbsp;31, 2016, there were 73,629,816 shares of
	our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger
	or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at
	prices and on terms to be determined at the time of sale.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	As of January&nbsp;31, 2016, there were 11,022,560 stock options and
	restricted stock units outstanding, 96,588 shares available for issuance under our Amended and Restated Stock Incentive Plan, and
	497,204 shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation
	grants outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future
	stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	If some or all of such shares are sold or otherwise issued into the
	public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
	all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
	Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
	in the future at a time and price that our management deems acceptable, or at all.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We have anti-takeover provisions in our corporate charter documents
	that may result in outcomes with which you do not agree.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our board of directors has the authority to issue up to 4,800,000
	shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
	further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
	adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
	parties to acquire a majority of our outstanding voting stock.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In addition, our certificate of incorporation provides for staggered
	terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
	and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
	of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
	more difficult a merger, tender offer or proxy contest involving us.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	We have never paid dividends on our common stock and do not anticipate
	doing so in the foreseeable future.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We have never paid cash dividends on our stock. We currently intend
	to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash
	dividends on our common stock in the foreseeable future.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Information Regarding Forward-Looking Statements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	This filing contains forward-looking statements within the meaning
	of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
	in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
	These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
	&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
	&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
	future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
	containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
	&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
	we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
	about:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the initiation, timing, progress and results of our preclinical testing, clinical trials, and to the extent applicable, post-marketing commitments, for our HAE product candidates, RAPIVAB, BCX4430, and our&nbsp;&nbsp;other research and development efforts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the further preclinical development, clinical development, commercialization, or post marketing studies by either us or partners of our product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties or profit from commercial sales of RAPIVAB by us or our partners;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the implementation of our business model, strategic plans for our business, products, product candidates and technology;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to establish and maintain collaborations or out-license rights to our drug candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	plans, programs, progress and potential success of our collaborations, including Seqirus UK Limited (&ldquo;SUL&rdquo;) for RAPIVAB, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Royalty Sub&rsquo;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates and technology;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to operate our business without infringing the intellectual property rights of others;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	estimates of our expenses, revenues, capital requirements, annual cash utilization and our needs for additional financing;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to raise additional capital to fund our operations;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our financial performance;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	competitive companies, technologies and our industry.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	These statements relate to future events or to our future financial
	performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
	or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
	statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
	listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
	and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
	and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
	any reason, even if new information becomes available in the future.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_003">
</A>
	ITEM&nbsp;1B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	UNRESOLVED STAFF COMMENTS
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	None.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_004">
</A>
	ITEM&nbsp;2.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	PROPERTIES
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	We lease property in both Durham, North Carolina and
	Birmingham, Alabama. Our headquarters, including our clinical and regulatory operations, are based in Durham, while our
	principal research facility is located in Birmingham. We currently lease approximately 15,000 square feet in Durham through
	June 30, 2020 and lease approximately 35,000 square feet in Birmingham through June&nbsp;30, 2016. We have recently leased an
	additional approximate 32,000 square foot facility in Birmingham through 2027 to house our new research facility. In October
	of 2015, we began construction of leasehold improvements on our new research facility and expect to move into the new
	facility in the third quarter of 2016. We believe that our facilities are adequate for our current operations.
</P>
</EFX_PROPERTIES>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_005">
</A>
	ITEM&nbsp;3.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	LEGAL PROCEEDINGS
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	None.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_006">
</A>
	ITEM&nbsp;4.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	MINE SAFETY DISCLOSURES
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	PART&nbsp;II
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_007">
</A>
	ITEM&nbsp;5.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	Market Information
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Our common stock trades on the NASDAQ Global Select Market under the
	symbol BCRX. The following table sets forth the low and high sales prices of our common stock as reported by the NASDAQ Global
	Select Market for each quarter in 2015 and 2014:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	First quarter
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.85
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.71
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.46
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13.33
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Second quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16.43
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.29
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.86
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Third quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10.26
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16.83
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.78
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14.62
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fourth quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.01
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.02
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13.28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The last sale price of the common stock on January&nbsp;29, 2016 as
	reported by the NASDAQ Global Select Market was $6.97 per share.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	Holders
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	As of January&nbsp;31, 2016, there were approximately 187 holders
	of record of our common stock
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	Dividends
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We have never paid cash dividends and do not anticipate paying cash
	dividends in the foreseeable future.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	Stock Performance Graph
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	This performance graph is not &#8220;soliciting material,&#8221; is
	not deemed filed with the SEC and is not to be incorporated by reference in any filing by us under the Securities Act or the Exchange
	Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The
	stock price performance shown on the graph is not necessarily indicative of future price performance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 0.25IN">
<B>
	PERFORMANCE GRAPH FOR BIOCRYST
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Indexed Comparison Since 2010
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_GRAPH.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Beginning
<BR>
	Investment
<BR>
	12/31/10
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Investment
<BR>
	at 12/31/11
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Investment
<BR>
	at 12/31/12
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Investment
<BR>
	at 12/31/13
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Investment
<BR>
	at 12/31/14
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Investment
<BR>
	at 12/31/15
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 34%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	BioCryst Pharmaceuticals, Inc.
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47.78
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27.47
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	147.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	235.20
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	199.61
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	NASDAQ Stock Market (U.S.)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.31
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	116.79
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	155.90
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	175.33
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	176.17
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	NASDAQ&nbsp;Pharmaceutical&nbsp;Stocks
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	117.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	134.31
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	182.23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	221.99
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	234.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The above graph measures the change in a $100 investment in our common
	stock based on its closing price of $5.17 on December&nbsp;31, 2010 and its year-end closing price thereafter. Our relative performance
	is then compared with the CRSP Total Return Indexes for the NASDAQ Stock Market (U.S.) and NASDAQ Pharmaceutical Stocks.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Recent Sales of Unregistered Securities: None.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Issuer Purchases of Equity Securities
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	There were no repurchases of our common stock or shares surrendered
	to satisfy tax obligations during the fourth quarter of 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_008">
</A>
	ITEM&nbsp;6.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	SELECTED FINANCIAL DATA
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The selected Statement of Operations Data and Balance Sheet data
	with respect to the years ended December&nbsp;31, 2015, 2014, 2013, 2012, and 2011 set forth below are derived from our consolidated
	financial statements. The selected financial data set forth below should be read in conjunction with &#8220;Management&#8217;s
	Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained in Item&nbsp;7 below and our consolidated
	financial statements and the notes thereto appended to this annual report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years Ended December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2011
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(In thousands, except per share amounts)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Statement of Operations Data:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total revenues
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,257
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,608
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,331
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	26,293
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,643
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cost of product sold
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,368
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Research and development expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	72,758
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51,796
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	41,943
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	49,160
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	55,538
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	General and administrative expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,047
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,461
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,007
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,130
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,692
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Royalty expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	528
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	121
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Restructuring costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,759
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(39,444
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,771
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,717
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(33,888
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(49,587
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(43,019
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,189
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,108
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(39,081
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(56,948
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.59
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.68
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.55
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.79
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.26
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Weighted average shares outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	72,901
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	66,773
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	55,216
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	49,474
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	45,144
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As of December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2011
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(In thousands)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Balance Sheet Data:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash, cash equivalents and investments
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100,858
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	114,038
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	40,788
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	37,058
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,725
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Receivables
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,243
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,490
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,115
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,562
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,831
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Inventory
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,612
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	683
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	263
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	124,555
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	136,874
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,866
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	82,208
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Long-term deferred revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,674
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,552
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,736
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,920
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,103
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Non-recourse notes payable
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(510,917
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(467,898
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(422,709
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(392,601
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(353,520
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total stockholders&#8217; equity (deficit)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47,724
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75,635
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,126
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(454
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,806
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_009">
</A>
	ITEM&nbsp;7.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
	This Annual Report on Form&nbsp;10-K contains certain statements
	of a forward-looking nature relating to future events or the future financial performance of BioCryst. Such statements are only
	predictions and the actual events or results may differ materially from the results discussed in the forward-looking statements.
	Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report, as well
	as those discussed in other filings made by BioCryst with the Securities and Exchange Commission.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
	The following Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;)
	is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement
	to, and should be read in conjunction with, our audited financial statements and the accompanying notes to the financial statements
	and other disclosures included in this Annual Report on Form&nbsp;10-K (including the disclosures under &#8220;Item&nbsp;1A. Risk
	Factors&#8221;).
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Cautionary Statement
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The discussion herein contains forward-looking statements within the
	meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
	created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
	based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
	within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
	requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
	and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
	on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
	of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
	from other sources.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	We operate in a highly competitive environment that involves a
	number of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
	including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
	regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
	need for future capital, competition associated with products, potential competition associated with our product candidates and
	retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our
	collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
	of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
	market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
	significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
	have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
	of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
	forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
	materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
	Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
	levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Our revenues are difficult to predict and depend on numerous factors,
	including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
	of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling
	procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related
	to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones
	by us or our collaborative partners.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Our operating expenses are also difficult to predict and depend
	on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
	drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability
	of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing
	and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective
	of our actions due to contractually committed activities and/or payments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	As a result of these factors, we believe that period to period
	comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of
	the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors.
	In such event, the prevailing market price of our common stock could be materially adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	Overview
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We are a biotechnology company that designs, optimizes and develops
	novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
	in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
	crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
	known as structure-guided drug design.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Critical Accounting Policies and Estimates
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The accompanying discussion and analysis of our financial condition
	and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
	in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
	that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
	We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
	regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
	accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
	manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Recent Corporate Highlights
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	RAPIVAB (peramivir injection)
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 5.75PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	RAPIVAB was approved by the FDA on December 19, 2014 for the treatment of acute uncomplicated influenza
	in adult patients who have been symptomatic for no more than two days. We have elected the &ldquo;Sell-Through&rdquo; revenue recognition
	methodology and recognized approximately $0.6 million of RAPIVAB product sales in 2015. With the approval, commercial availability
	and out-licensing collaboration of RAPIVAB, we have moved our focus to: (1) obtaining a stockpiling procurement contract with the
	U.S. Government to realize the strategic value of this program; (2) fulfilling our post-approval development requirements, including
	conducting a pediatric trial; and (3) submitting a MAA and a NDS in the European Union and Canada, respectively, to allow SUL (defined
	below) the ability to commercialize the drug in those regions.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	On June 16, 2015, we and Seqirus UK Limited, a limited company organized
	under the laws of the UK ("SUL") and a subsidiary of CSL, entered into a License Agreement (the "SUL Agreement")
	granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
	treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
	together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
	currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
	in the world. We retain all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. government,
	while SUL has the right to pursue government stockpiling outside the U.S.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Pursuant to the SUL Agreement, RAPIVAB will be commercialized by
	CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global
	markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
	of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole
	decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible
	for all associated costs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Under the terms of the SUL Agreement, we are responsible for fulfilling
	all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment we will transfer
	ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the European
	Union (&#8220;EU&#8221;), we are also responsible for regulatory filings and interactions with the Health Products and Food Branch
	of Health Canada ("Health Canada") and the European Medicines Agency ("EMA") until marketing approval for RAPIVAB
	is obtained and assigned to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering committee, composed of
	an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization
	of RAPIVAB in the Territory and any additional development.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Under the terms of the SUL Agreement, we received an upfront payment
	of $33.7 million, and we may receive up to $12.0 million in additional milestone payments related to the successful achievement
	of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult
	indication in the EU and (iii) by Health Canada for an adult indication in Canada. We are also entitled under the SUL Agreement
	to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales,
	as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically,
	we receive tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year
	(defined as July 1 &#8211; June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in
	the Territory, other than in the U.S., during a Contract Year, each subject to certain downward adjustments for circumstance or
	events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and
	expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years
	from the date of the SUL Agreement (the "Royalty Term").&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
<I>
	HAE Program
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Avoralstat
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	On December 18, 2014, we announced
	the dosing of the first patient in OPuS-2 (
<B>
	O
</B>
	ral
<B>
	P
</B>
	rophylaxi
<B>
	S-2
</B>
	), a blinded, randomized, placebo-controlled
	clinical trial of orally-administered avoralstat in patients with hereditary angioedema (&ldquo;HAE&rdquo;). OPuS-2 was a 12-week,
	three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of avoralstat, 300 mg and 500 mg, administered
	three-times daily compared with placebo. This trial was conducted in the U.S. and select European countries. The primary efficacy
	endpoint for the trial was the mean angioedema attack rate for each avoralstat dose group compared to placebo. On February 8, 2016,
	we announced results from OPuS-2.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	In the OPuS-2 study, HAE patients with a historical attack
	frequency of greater than 0.45 attacks per week were randomized to treatment with either 500 mg or 300 mg of avoralstat, or placebo,
	administered three times daily for 12 weeks. Thirty-eight subjects received avoralstat 500 mg, 36 subjects received avoralstat
	300 mg, and 36 subjects received placebo. Treatment with 500 mg and 300 mg of avoralstat three times daily failed to demonstrate
	a statistically significantly lower mean attack rate versus placebo. The mean (standard deviation) attack rates per week were 0.63
	(0.57) on avoralstat 500mg and 0.71 (0.66) on avoralstat 300mg, compared to 0.61 (0.41) on placebo.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Statistically
	significant improvements in duration of attacks and in the Angioedema Quality of Life total score were observed comparing the 500
	mg three times a day avoralstat arm to placebo. Following the analysis of OPuS-2 results, the decision was made to discontinue
	further development of softgel avoralstat formulation in order to focus development efforts on a novel solid dosage form of avoralstat
	to achieve meaningfully better drug exposure. We expect additional avoralstat results from a relative bioavailability study testing
	a novel solid dosage form of avoralstat by mid-year 2016. The primary goals of this study are to achieve meaningfully better drug
	exposures and twice daily dosing.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	BCX7353 and other 2nd generation HAE compounds
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	In January 2015, we selected BCX7353 to advance into Phase 1 development
	as a once-daily, oral prophylactic HAE treatment. BCX7353 is structurally different from avoralstat, but has a similar mechanism
	of action targeting plasma kallikrein. On May 13, 2015, we announced the initiation of a Phase 1 clinical trial to evaluate the
	safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 12PT 0 0">
	On October 8, 2015, we announced that the randomized, placebo-controlled,
	Phase 1 clinical trial of orally-administered BCX7353 in healthy volunteers successfully met all of its objectives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	In this Phase 1 clinical trial BCX7353 dose levels included
	single doses of up to 1000mg, once-daily doses of up to 500 mg for seven days, and once-daily doses of 350 mg for 14 days. Plasma
	levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with food. The half-life of BCX7353
	was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target therapeutic range throughout
	the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay.
	Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the degree of inhibition was dose-related
	(p &lt; 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This pharmacodynamic effect correlated strongly
	to the achieved drug concentration (r = 0.91, p &lt; 0.0001).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	Subsequently, cohorts of healthy Japanese volunteers were added
	to the study to support development of BCX7353 in Japan under the &ldquo;Sakigake&rdquo; accelerated R&amp;D designation. Following assessment
	of single oral doses of BCX7353 of 100mg (6 subjects) and 500 mg (6 subjects), 250 mg of BCX7353 was administered orally and daily
	for seven days to ten subjects. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects
	were moderately higher. Kallikrein inhibition on day seven of daily dosing with 250 mg in Japanese subjects was similar to that
	seen at the 350 mg daily and 500 mg daily dose levels in Western subjects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	The combined data from both Western and Japanese healthy volunteers
	indicates that oral BCX7353 has been generally safe and well tolerated in a total of 96 treated healthy volunteers, 46 with singles
	doses and 50 with multiple doses. No serious adverse events have been seen and no dose-limiting toxicity has been identified. There
	have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	In single dose subjects, 89% (31 of 35) of adverse events (AEs)
	have been grade 1. The four grade 2 AEs observed were: nausea (1) and vomiting (1) occurring in one subject: hay fever (1) and
	diarrhea (1 from Japanese cohort).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	In multiple dose subjects, 90% (63 of 70) of adverse
	events (AEs) have been grade 1. The six grade 2 AEs observed were; upper abdominal pain (1, discontinued from study); syncope
	(1) headache (1) diarrhea (1) and upper abdominal pain (1) occurring on one subject (discounted from study), and
	maculopapular rash. One grade 3 AE was observed, a cutaneous delayed-type hypersensitivity reaction. The two rash AE&rsquo;s
	are described in more detail below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	The incidence of drug-related skin rash across all multiple-dose
	cohorts was 4% (2 of 50 subjects). One Japanese subject dosed at 250 mg daily for seven days developed a grade 2 maculopapular
	skin rash following cessation of dosing, and one Western subject dosed at 500 mg daily for seven days developed a grade 3 hypersensitivity
	reaction, described as a maculopapular skin rash, following cessation of dosing. Both AEs were assessed by the investigator as
	drug-related. The Japanese subject received antihistamines and the Western subject received corticosteroids, and in both cases
	the rash resolved within a few days.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 12PT 0 0">
	The safety, tolerability, drug exposure and on-target plasma
	kallikrein inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase
	2 trial (&ldquo;APeX-1&rdquo;) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353
	as a preventative treatment to reduce the frequency of attacks in HAE patients is expected to begin in 2016. The design of the
	trial will be described when the APeX-1 protocol is approved by regulatory authorities and the clinical trial is initiated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	On October 27, 2015 the Japanese Ministry of Health Labor &amp;
	Welfare (&ldquo;MHLW&rdquo;) announced that BioCryst&rsquo;s BCX7353 was one of six products designated under MHLW&rsquo;s new
	Sakigake fast track review system. The Sakigake Designation System promotes R&amp;D in Japan, aiming at early practical
	application for innovative pharmaceutical products. This designation provides for additional interactions with the regulatory agency
	in Japan from early development through filing, and prioritized development and review, with the aim of introduction of the product
	as soon as possible to address a serious unmet medical need. We expect the results of APeX-1 to help us and the MHLW to determine
	the regulatory pathway and timeline for BCX7353 in Japan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	Other 2
<SUP>
	nd
</SUP>
	generation&nbsp;HAE compounds
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	In addition to BCX7353, we have succeeded in inventing several
	uniquely different plasma kallikrein inhibitor molecules from distinct structural classes. Accordingly, we have selected additional
	drug candidates that have suitable pharmacologic properties to advance into preclinical development. The development of these candidates
	for HAE or in other therapeutic areas is ongoing and additional disclosure on these compounds will occur as we near IND filings
	of these compounds.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 20PT; TEXT-INDENT: 0PT">
<B>
<I>
	BCX4430
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	On December 15, 2014, we announced the dosing of the first subject
	in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The
	main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
	administered via i.m. injection in healthy subjects. This Phase 1 study is expected to continue in 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	On December 23, 2014, we announced results from a successful proof-of-concept
	study of BCX4430 for the treatment of experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary
	goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus.
	Dosing of&nbsp;placebo or BCX4430 by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice a day
	for 14 days. The overall survival rate for BCX4430 treated animals at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls).
	Preliminary evaluation of the quantity of virus in the blood showed an approximate 3-log reduction in Ebola virus RNA copies/mL
	of plasma, compared with control animals. This Rhesus macaques study was conducted following the completion, in November 2014,
	of a dose-ranging study of BCX4430 for the treatment of cynomolgus macaques infected with Ebola virus. The cynomolgus macaques
	study was designed to evaluate whether BCX4430 showed a meaningful benefit for survival in Ebola virus NHP disease models. In this
	study, BCX4430 demonstrated a statistically significant prolongation of survival for the animals at the highest dose regimen tested,
	but no animals survived beyond 21 days.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	Results of Operations
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Year Ended December&nbsp;31, 2015 Compared to 2014
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Total 2015 revenues increased to $48.3 million as compared to 2014
	revenues of $13.6 million. The increase in 2015 was primarily due to recognizing revenue associated with the SUL out-licensing
	transaction, RAPIVAB product revenue and increased collaboration revenue associated with BCX4430 development. The 2015 revenue
	consisted of $5.7 million of RAPIVAB product revenue and $21.8 million of collaborative revenue related to the SUL Agreement, $2.4
	million of royalty revenue from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan and
	Korea, $16.3 million of reimbursement of collaborative expenses from BARDA/HHS and NIAID/HHS related to the development of peramivir
	and BCX4430, and $1.4 million associated with collaborative revenue amortization from other corporate partnerships. In addition,
	we recorded approximately $618,000 of RAPIVAB revenue under the &ldquo;Sell-Through&rdquo; revenue recognition methodology, but
	going forward will recognize all future commercial RAPIVAB sales as royalty revenue under one of our partnership arrangements.
	RAPIVAB was available for commercial sale on December 26, 2014. The 2014 revenue consisted of $3.0 million of royalty revenue from
	Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $9.4 million of reimbursement of collaborative
	expenses from BARDA/HHS related to the development of peramivir, $1.2 million associated with collaborative revenue amortization
	from other corporate partnerships and $33,000 of RAPIVAB revenue. With the expiration of BARDA/HHS peramivir contract, unless we
	enter into new government contracts, all significant and future reimbursement of collaborative expenses will be under the NIAID/HHS
	and BARDA/HHS BCX4430 development contracts. Our RAPIVAB product revenue will be difficult to predict because of volatility in
	prevalence, timing and severity of influenza season to season.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Research and Development (&ldquo;R&amp;D&rdquo;) expenses increased to $72.8 million in 2015 from $51.8
	million in 2014. 2015 R&amp;D expenses, compared with 2014, reflect increased spending on our HAE programs and slightly higher
	spending on our RAPIVAB program. In addition, our 2014 equity compensation expense allocated to R&amp;D increased due to the vesting
	of two underlying milestones under previously issued performance-based stock options for the successful outcome of OPuS-1 and RAPIVAB
	approval in the U.S.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The following table summarizes our R&amp;D expenses for the
	periods indicated (amounts are in thousands).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	R&amp;D expenses by program:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Avoralstat
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,769
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,005
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15,442
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	BCX7353
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,819
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Other 2nd generation HAE compounds
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,320
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,681
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	BCX4430
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,400
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,060
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,318
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Peramivir
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,690
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,898
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,627
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Other research, preclinical and development costs
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,760
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,152
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,556
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total R&amp;D expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	72,758
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51,796
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	41,943
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	R&amp;D expenses include all direct and indirect expenses and are
	allocated to specific programs at the point of development of a lead product candidate. Direct expenses are charged directly to
	the program to which they relate and indirect expenses are allocated based upon internal direct labor hours dedicated to each respective
	program. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies,
	develop manufacturing processes, manufacture the product candidates, conduct and manage clinical trials, as well as other costs
	related to our clinical and preclinical studies. Indirect R&amp;D expenses consist of lab supplies and services, facility expenses,
	depreciation of development equipment and other overhead of our research and development efforts. R&amp;D expenses vary according
	to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs
	tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of
	patients enrolled in these clinical trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Selling, General and administrative (&ldquo;SG&amp;A&rdquo;) expenses
	increased to $13.0 million in 2015 compared to $7.5 million in 2014. The increase of $5.5 million is primarily associated with
	increased marketing and medical affairs activities associated with our HAE programs, as well as unrestricted grants awarded to
	the U.S. and international HAE patient advocacy groups.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Interest expense, related to the non-recourse notes issued in conjunction
	with the peramivir royalty monetization transaction in March 2011, increased slightly to $5.2 million in 2015 as compared to $5.0
	million in 2014. In addition, a mark to market loss of $0.6 million was recognized in 2015 related to the foreign currency hedge
	entered into in conjunction with the royalty monetization transaction, compared to a mark to market gain of $5.5 million in 2014,
	both resulting from changes in the U.S. dollar/Japanese yen exchange rate during the respective years. In addition, a realized
	currency exchange gain of $1.6 million was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option
	under our foreign currency hedge. Thus, a resulting $1.1 million net gain is recognized on our foreign currency derivative for
	2015. We entered into a foreign currency hedge agreement to hedge changes in the value of the Japanese yen relative to the U.S.
	dollar. The currency hedge does not qualify for hedge accounting treatment and therefore mark to market adjustments are recognized
	in our Consolidated Statements of Comprehensive Loss. Although we cannot predict the future yen/dollar exchange rate, the applicable
	foreign currency rates moved such that we currently have no collateral posted; however, it is possible that collateral will be
	required in 2016 or the future. We are unable to predict future changes in the yen/dollar exchange rate or increases/decreases
	in our hedge loss associated with the currency hedge agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Year Ended December&nbsp;31, 2014 Compared to 2013
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Total 2014 revenues decreased to $13.6 million as compared to 2013
	revenues of $17.3 million. The 2014 revenue consisted of $3.0 million of royalty revenue from Shionogi and Green Cross associated
	with sales of peramivir in Japan and Korea, $9.4 million of reimbursement of collaborative expenses from BARDA/HHS and NIAID/HHS
	related to the development of peramivir and BCX4430, and $1.2 million associated with collaborative revenue amortization from other
	corporate partnerships. In addition, we recorded approximately $33,000 of RAPIVAB revenue under the &#8220;Sell-Through&#8221;
	revenue recognition methodology. RAPIVAB was available for commercial sale on December 26, 2014. The decrease in total revenues
	was primarily the result of the June 2014 BARDA/HHS peramivir contract expiration associated with completion of development activities
	under this contract. The 2013 revenue consisted of $2.6 million of royalty revenue from Shionogi and Green Cross associated with
	sales of peramivir in Japan and Korea, $13.5 million of reimbursement of collaborative expenses from BARDA/HHS related to the development
	of peramivir and $1.2 million associated with collaborative revenue amortization from other corporate partnerships. With the expiration
	of BARDA/HHS peramivir contract, unless we enter into new government contracts, all significant and future reimbursement of collaborative
	expenses will be under the NIAID/HHS BCX4430 development contract. In addition, we expect RAPIVAB product sales to increase in
	future years when the product is available prior to the beginning of the influenza season and for a longer period of time within
	a fiscal year. However, our RAPIVAB product revenue will be difficult to predict because of volatility in prevalence, timing and
	severity of influenza season to season in the United States and because we will not incur substantial commercialization expenses
	to promote it.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	R&amp;D expenses increased to $51.8 million in 2014 from $41.9 million
	in 2013. 2014 R&amp;D expenses, compared with 2013, reflect increased spending on our HAE and BCX4430 programs which were partially
	offset by the wind-down of peramivir development activities and the expiration of the BARDA/HHS development contract. In addition,
	our 2014 equity compensation expense allocated to R&amp;D increased due to the vesting of two underlying milestones under previously
	issued performance-based stock options for the successful outcome of OPuS-1 and RAPIVAB approval in the U.S. In 2013, we recognized
	approximately $5.0 million of R&amp;D costs related to a write-off of deferred collaboration costs associated with our PNP licensing
	agreement with AECOM/IRL. This write-off, and related R&amp;D expenses, was allocated to the ulodesine program and represents the
	majority of 2013 ulodesine expense represented in the table below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 12PT 0 0">
	SG&amp;A expenses increased to $7.5 million in 2014 compared
	to $6.0 million in 2013. The increase of $1.5 million is primarily due to RAPIVAB distribution expenses and unrestricted grants
	awarded to U.S. and international HAE patient advocacy groups. We expect our future SG&amp;A expenses to increase due to increases
	in administrative expenses associated with corporate growth in preparation for future NDA and other regulatory filings and for
	product commercialization.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Interest expense, related to the non-recourse notes issued in conjunction
	with the peramivir royalty monetization transaction in March 2011, increased slightly to $5.0 million in 2014 as compared to $4.8
	million in 2013. In addition, a mark to market gain of $5.5 million was recognized in 2014 related to the foreign currency hedge
	entered into in conjunction with the royalty monetization transaction, compared to a mark to market gain of $5.3 million in 2013,
	both resulting from changes in the U.S. dollar/Japanese yen exchange rate during the respective years.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Cash expenditures have exceeded revenues since our inception and
	we expect our 2016 operating expenses to exceed our 2016 revenues. Our operations have principally been funded through public offerings
	and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S.
	Government contracts for peramivir and BCX4430; and to a lesser extent, the PhaRMA Notes financing. To date, we have been awarded
	a BARDA/HHS peramivir development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS BCX4430 development
	contract totaling $34.0 million, which is ongoing, and a BARDA/HHS BCX4430 development contract totaling $36.2 million, which is
	also ongoing. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options in the active contracts is $29.9&nbsp;million
	and $16.3 million, respectively. Most recently, we completed a successful public offering in June 2014 of 11.5 million shares of
	common stock at a price of $10.00 per share, which provided net proceeds to us of approximately $107.8 million. This financing
	and the recently completed SUL out-licensing transaction provides us liquidity through mid-2017. We may issue securities through
	private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC. In addition
	to the above, we have received funding from other sources, including other collaborative and other research and development agreements;
	government grants; equipment lease financing; facility leases; research grants; and interest income on our investments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, we had net working capital of $1.5 million, a decrease of approximately
	$30.6 million from $32.1 million at December&nbsp;31, 2014. The decrease in working capital was principally due to our normal operating
	expenses associated with the development of our product candidates and the reclassification of our non-recourse notes payable to
	current liabilities. Our principal sources of liquidity at December&nbsp;31, 2015 were approximately $28.9 million in cash and
	cash equivalents; approximately $70.3 million in investments considered available-for-sale, and approximately $5.5 million in U.S.
	Government receivables. We anticipate our cash and investments will fund our operations through mid-2017.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We intend to contain costs and cash flow requirements by closely managing
	our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
	research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
	losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
	incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
	property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
	of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
	to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
	and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
	investments.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We extended or executed additional lease obligations in 2015 for our
	Birmingham, Alabama operations which increased the obligations by $5.6 million and extended the new obligations out to 2027. These
	operating lease obligations encompass future rental obligations of our Birmingham operating facilities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We plan to finance our needs principally from the following:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	lease or loan financing and future public or private equity financing;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our existing capital resources and interest earned on that capital;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	payments under existing and executing new contracts with the U.S. Government; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	payments under collaborative and licensing agreements with corporate partners.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	As our programs continue to advance, our costs will increase. Our
	current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
	additional personnel resources and testing required for the continuing development of our product candidates will consume significant
	capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
	on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
	our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for BCX4430, the amount
	of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for
	the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
	trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
	progression of our other programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	With the funds available at December 31, 2015, we believe these
	resources will be sufficient to fund our operations through mid-2017. Our future liquidity needs, and ability to address those
	needs, will largely be determined by the success of our product candidates and key development and regulatory events in the future.
	In order to continue our operations substantially beyond mid-2017, we will need to: (1)&nbsp;successfully secure or increase U.S.
	Government funding of our programs, including procurement contracts; (2)&nbsp;out-license rights to certain of our products or
	product candidates, pursuant to which we would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt
	financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue
	and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations.
	We may issue securities through private placement transactions or registered public offerings pursuant to a registration statement
	filed with the SEC.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Our long-term capital requirements and the adequacy of
	our available funds will depend upon many factors, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the magnitude of work under our government contracts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the progress and magnitude of our research, drug discovery and development programs;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	changes in existing collaborative relationships or government contracts;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	successful commercialization of marketed products by either us or a partner;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the scope and results of preclinical studies and clinical trials to identify and develop product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to engage sites and enroll subjects in our clinical trials;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	increases in personnel and related costs to support the development and commercialization of our product candidates;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the scope of manufacturing of our drug substance and product candidates required for future NDA filings;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	competitive and technological advances;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the time and costs involved in obtaining regulatory approvals;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	post-approval commitments for RAPIVAB and other products that receive regulatory approval; and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	We expect that we will be required to raise additional capital
	to complete the development and commercialization of our current product candidates and we may seek to raise capital in the future.
	Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate
	partners or from other sources, including governmental agencies in general and existing government contracts specifically, may
	not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
	with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
	of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
	may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
	back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
	for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
	rate of reimbursement by U.S. Government agencies of our BCX4430 expenses and any future decisions regarding the future of the
	RAPIVAB and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements
	will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates;
	obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and
	changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of
	business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing
	processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Financial Outlook for 2016
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Based upon our development plans, expected operations and our awarded
	government contracts, we expect 2016 operating cash usage to be in the range of $55 to $75 million, and expect our total 2016 operating
	expenses to be in the range of $78 to $98 million. Our operating expense range excludes equity-based compensation expense due to
	the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of the Company&rsquo;s
	stock, as well as vesting of the Company&rsquo;s outstanding performance-based stock options. Our operating cash forecast excludes
	any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows.
	Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated
	or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere
	in this report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, we are not involved in any unconsolidated
	entities or off&#8211;balance sheet arrangements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Contractual Obligations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In the table below, we set forth our enforceable and legally binding
	obligations and future commitments and obligations related to all contracts that we are likely to continue regardless of the fact
	that they are cancelable as of December&nbsp;31, 2015. Some of the amounts we include in this table are based on management&#8217;s
	estimates and assumptions about these obligations, including their duration, the possibility of renewal, anticipated actions by
	third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the obligations we will actually
	pay in future periods may vary from those reflected in the table.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Payments Due by Period
<BR>
	(In thousands)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Contractual Obligations
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Less&nbsp;Than
<BR>
	1&nbsp;Year
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	1-3&nbsp;Years
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	3-5&nbsp;Years
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	More&nbsp;Than
<BR>
	5&nbsp;Years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating lease obligations
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,908
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	651
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,741
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,471
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,045
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Purchase obligations(1)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	34,137
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	34,137
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contingent license obligations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	225
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	450
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	425
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	900
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Non-recourse notes payable(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,396
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,946
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,400
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38,050
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100,441
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	45,959
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,591
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39,946
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,945
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 96%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Purchase obligations include commitments related to clinical development, manufacturing and research operations and other purchase commitments.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Assumes the PhaRMA Notes will be repaid at maturity and the related interest costs will accrue and be paid annually through maturity. This assumption is based on the unpredictable nature of the royalty payments from Shionogi, which are designated for both principal and interest payments on the PhaRMA Notes.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Under the Currency Hedge Agreement, we have the right to purchase
	dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2016 through
	2020. A payment of $2.0 million will be required if, during the relevant year, the dollar is worth 100 yen or less. As of December&nbsp;31,
	2015, we have no hedge collateral posted against the Currency Hedge Agreement. Because the posting of additional collateral and
	payment of annual premiums is contingent on the value of the yen relative to the dollar and other factors, such payments have been
	excluded from the foregoing table.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In addition to the above, we have committed to make potential future
	&#8220;sublicense&#8221; payments to third-parties as part of in-licensing and development programs. Payments under these agreements
	generally become due and payable only upon achievement of certain developmental, regulatory and/or commercial milestones. Because
	the achievement of these milestones is neither probable nor reasonably estimable, such contingencies have not been recorded on
	our balance sheet.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Critical Accounting Policies
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We have established various accounting policies that govern the application
	of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
	significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
	Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
	are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
	nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
	could have a material impact on the carrying values of assets and liabilities and the results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	While our significant accounting policies are more fully described
	in Note&nbsp;1 to our consolidated financial statements included in this Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
	2015, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating
	our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial
	statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Inventory
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Our inventories consist of RAPIVAB finished goods and work in process,
	which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
	overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
	of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
	we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
	addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval
	of RAPIVAB in December 2014, we began capitalizing costs associated with the production of RAPIVAB commercial inventories.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Accrued Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We enter into contractual agreements with third-party vendors who
	provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
	are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
	these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
	purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
	of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
	of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
	each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
	with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to investigative sites in connection with clinical trials;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	professional fees.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We base our expenses related to clinical trials on our estimates of
	the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
	manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
	contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
	enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
	which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
	or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
	begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We recognize revenues from collaborative and other research and development
	arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
	evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
	price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 23PT">
<I>
	Collaborative and Other Research and Development Arrangements and Royalties
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 23PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Revenue from license fees, royalty payments, event payments, and
	research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing
	performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under
	licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by
	management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables,
	we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as
	a result of changes in the estimated revenue period are recognized prospectively.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Under certain of our license agreements, we receive royalty payments
	based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
	amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	For arrangements that involve the delivery of more than one element,
	each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
	This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
	is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
	The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
	evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
	(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
	by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
	consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
	consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
	use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
	performance obligation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In June 2015, we entered into a License Agreement (the "SUL Agreement")
	granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize
	RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments,
	and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii)
	regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which
	$7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.8
	million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately
	$3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory
	transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected
	period of involvement in these regulatory support activities.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Milestone payments are recognized as licensing revenue upon the achievement
	of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
	at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
	these revenue recognition criteria are recorded as deferred revenue.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Under the terms of the SUL Agreement, we may receive up to $12.0
	million in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
	by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult
	indication in Canada. We evaluated each event based payment under the provisions of ASU 2010-17,
<I>
	Milestone Method of Revenue
	Recognition
</I>
	, and determined that each event based payment met the criteria to be considered substantive and represents a milestone
	under the milestone method of accounting. No event based payments were achieved during the periods presented.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Reimbursements received for direct out-of-pocket expenses related
	to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
	our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Product Sales
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	We recognize revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership
	have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the
	Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement
	exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized
	net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, prior to completion of the
	SUL transaction, we sold RAPIVAB to specialty distributors, who, in turn, sell to physician offices, hospitals and federal, state
	and commercial health care organizations.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Sales deductions consist of statutory rebates to state Medicaid, Medicare
	and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
	recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
	from historical experience adjusted to reflect known changes in the factors that impact such reserves.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	We utilize data from external sources to help estimate gross-to-net
	sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited
	to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and
	information from third-party suppliers of market research data to the pharmaceutical industry.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	We have categorized and described more fully the following significant
	sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires
	us to use information from external sources.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Rebates and Chargebacks
</I>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Statutory rebates to state Medicaid agencies and Medicare are based
	on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
	on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs
	relating to RAPIVAB sales.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Chargebacks claimed by specialty distributors are based on the differentials
	between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
	covered under federally qualified programs.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The amount of the reserve for rebates and chargebacks is based
	on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
	experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
	and statutory or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit
	plans, and the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party
	suppliers of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record
	any necessary adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of
	sale. To the extent actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may
	need to be reversed, either of which would impact current period product revenue.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Discounts and Sales Incentives
</I>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Discounts and other sales incentives primarily consist of Inventory
	Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee
	based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales
	to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual
	rates to such sales.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Product Returns
</I>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We do not record a product return allowance as we do not offer the
	ability to return goods once a bona fide shipment has been accepted by a specialty distributor.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Our research and development costs are charged to expense when incurred.
	Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
	and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
	Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
	clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
	various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
	by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
	and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Additionally, we have license agreements with third parties, such
	as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
	as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
	over the related revenue recognition period. We expense maintenance payments as incurred.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Deferred collaboration expenses represent sub-license payments paid
	to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
	partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
	of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
	recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We group our R&amp;D expenses into two major categories: direct external
	expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct
	laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials,
	as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect
	expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our
	research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery
	research efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	All share-based payments, including grants of stock option awards
	and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
	Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
	on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
	assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
	term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
	basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
	the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
	adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
	expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
	estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
	changes in estimates, may differ substantially from our current estimates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Foreign Currency Hedge
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In connection with our issuance of the PhaRMA Notes, we entered into
	a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
	the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
	per dollar for which we may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement
	remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
	worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
	Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
	volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
	remaining payable under the Currency Hedge Agreement. In establishing the hedge, we provided initial funds of approximately $2.0&nbsp;million
	to support our potential hedge obligations. As of December 31, 2015, the maximum amount of hedge collateral we may be required
	to post is $9.8 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Currency Hedge Agreement does not qualify for hedge accounting
	treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark
	to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs
	are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting
	principles (&ldquo;U.S. GAAP&rdquo;). The Company is also required to post collateral in connection with the mark to market adjustments
	based on defined thresholds. As of December&nbsp;31, 2015, no collateral was posted under the agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Tax
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We account for uncertain tax positions in accordance with U.S. GAAP.
	Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities
	and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential
	tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses
	carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions
	in which we operate and the period over which our deferred tax assets will be recoverable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Impact of Inflation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We do not believe that our operating results have been materially
	impacted by inflation during the past three years. However, we cannot be assured that our operating results will not be adversely
	affected by inflation in the future. We will continually seek to mitigate the adverse effects of inflation on the services that
	we use through improved operating efficiencies and cost containment initiatives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Recent Accounting Pronouncements
</B>
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Note&nbsp;11 to the Consolidated Financial Statements included in
	Item&nbsp;8 of this Annual Report on Form&nbsp;10-K discusses accounting pronouncements recently issued or proposed but not yet
	required to be adopted.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_010">
</A>
	ITEM&nbsp;7A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Interest Rate Risk
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	We are subject to interest rate risk on our investment portfolio
	and borrowings under our PhaRMA Notes.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We invest in marketable securities in accordance with our investment
	policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
	and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
	exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
	commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
	in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
	to fluctuate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Our investment exposure to market risk for changes in interest rates
	relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value
	due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses.
	Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure
	portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not
	significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our
	fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will
	be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations
	due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market
	value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers.
	To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding
	the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest
	rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant
	losses from our investments.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We do not use interest rate derivative instruments to manage exposure
	to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
	and reinvestment risk. We reduce default risk by investing in investment grade securities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Foreign Currency Risk
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The majority of our transactions occur in U.S. dollars and we do not
	have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency
	exchange risk in our normal operations.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In connection with the issuance by Royalty Sub of the PhaRMA Notes,
	we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
	to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
	the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains
	in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2016 through May&nbsp;2020.
	Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
	in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET_RISK>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_011">
</A>
	ITEM&nbsp;8.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_022616P_HTM_A_012">
</A>
	CONSOLIDATED BALANCE SHEETS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="BALANCE-SHEET">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	ASSETS
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,899
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54,540
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Restricted cash
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,612
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	150
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Investments
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22,664
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18,232
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Receivables from collaborations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,243
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,849
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Receivables from product sales
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,641
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Inventory
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,612
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	683
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,870
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,172
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Deferred collaboration expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	76
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Total current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	65,990
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	89,343
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Investments
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47,683
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	41,116
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Property and equipment, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,149
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	207
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred collaboration expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	265
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	177
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,468
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,031
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	124,555
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	136,874
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	LIABILITIES AND STOCKHOLDERS&#8217; EQUITY
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accounts payable
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,307
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,849
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,237
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,329
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Interest payable
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,746
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,029
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred collaboration revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,163
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,481
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred product sales revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,605
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Non-recourse notes payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Total current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64,453
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,293
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred collaboration revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,674
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,552
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred rent
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	329
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	394
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Lease financing obligation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,375
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stockholders&#8217; equity:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Preferred stock, $0.001 par value; shares authorized&nbsp;&#8212;&nbsp;5,000; no shares outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Common stock, $0.01&nbsp;par value; shares authorized&nbsp;&#8212;&nbsp;200,000; shares issued and outstanding&nbsp;&#8212;&nbsp;73,355 in 2015 and 71,955 in 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	734
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	720
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Additional paid-in capital
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	558,113
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	542,943
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accumulated other comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(206
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(130
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(510,917
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(467,898
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Total stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47,724
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75,635
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total liabilities and stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	124,555
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	136,874
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BALANCE_SHEET>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_022616P_HTM_A_013">
</A>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="INCOME">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Revenues
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Product sales, net
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,291
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Royalty revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,386
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,025
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,562
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Collaborative and other research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39,580
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,769
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total revenues
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,257
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,608
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,331
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cost of products sold
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,368
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	72,758
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51,796
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	41,943
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Selling, general and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,047
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,461
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,007
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Royalty
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	528
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	121
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	87,701
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59,379
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,048
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(39,444
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,771
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,717
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Interest and other income
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	535
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	93
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	93
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Interest expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,998
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,778
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Gain on foreign currency derivative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,090
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,487
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,294
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(43,019
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,189
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,108
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Basic and diluted net loss per common share
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.59
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.68
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.55
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Weighted average shares outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	72,901
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	66,773
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	55,216
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Unrealized loss on available for sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(134
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(43,095
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,323
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,131
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	&nbsp;
</B>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 6PT">
<B>
<A NAME="F10K_022616P_HTM_A_014">
</A>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 6PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="CASH-FLOWS">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(43,019
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,189
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,108
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Depreciation, amortization, and impairment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	180
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	177
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	304
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Loss (gain) on disposal of property and equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(47
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,705
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,177
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,368
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Amortization of debt issuance costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Change in fair value of foreign currency derivative
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	564
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,487
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,294
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Changes in operating assets and liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Receivables
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,247
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,375
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,447
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Inventory
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(929
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(683
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Prepaid expenses and other assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,207
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,943
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(620
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Deferred collaboration expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(102
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,133
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable and accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,393
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,818
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,049
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Deferred revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,199
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,429
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net cash used in operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(13,116
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(38,551
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(26,530
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Investing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Acquisition of property and equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,122
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(106
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds from sale of property and equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Change in restricted cash
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,462
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	157
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Purchases of investments
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(53,830
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(73,875
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23,974
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Sales and maturities of investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	42,410
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	34,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,330
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net cash used in investing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(18,004
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(39,980
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(3,467
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Financing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Sale of common stock, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106,600
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	23,633
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Exercise of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,124
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,997
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,333
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Employee stock purchase plan sales
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	355
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	310
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	124
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Receipt of foreign currency derivative
	collateral
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,180
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net cash provided by financing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,479
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	111,907
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	30,270
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(Decrease) increase in cash and cash equivalents
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(25,641
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	33,376
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	273
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54,540
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,164
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,891
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Cash and cash equivalents at end of year
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	28,899
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54,540
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,164
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CASH_FLOW>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<A NAME="F10K_022616P_HTM_A_015">
</A>
<B>
	CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
	EQUITY (DEFICIT)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="STOCKHOLDERS-EQUITY">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Common
<BR>
	Stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Additional
<BR>
	Paid-In
<BR>
	Capital
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accumulated
<BR>
	Other
<BR>
	Comprehensive
<BR>
	(Loss) Income
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accumulated
<BR>
	Deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
<BR>
	Stockholders&rsquo;
<BR>
	Equity&nbsp;(Deficit)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Balance at Decembe
<FONT STYLE="FONT-SIZE: 10PT">
	r 31, 2012
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	509
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	391,611
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(392,601
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(454
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,108
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30,108
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Other comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Exercise of stock options, 563 shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,327
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,333
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Employee stock purchase plan sales, 89&nbsp;shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	123
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	124
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock, 7,547 shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	23,559
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	23,634
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,368
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,368
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	Balance at December&nbsp;31, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	591
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	420,988
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(422,709
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,126
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,189
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,189
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Other comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(134
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(134
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Exercise of stock options, 1,314 shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,984
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,997
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Employee stock purchase plan sales, 49&nbsp;shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	309
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	310
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock, 11,500 shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106,485
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106,600
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,177
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,177
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	Balance at December&nbsp;31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	720
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	542,943
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(130
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(467,898
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	75,635
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(43,019
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(43,019
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Other comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Exercise of stock options, 1,359 shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,110
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,124
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Employee stock purchase plan sales, 41&nbsp;shares, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	355
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	355
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,705
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,705
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	Balance at December&nbsp;31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	734
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	558,113
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(206
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(510,917
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	47,724
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
<A NAME="F10K_022616P_HTM_A_016">
</A>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Note&nbsp;1&nbsp;&#8212; Significant Accounting Policies and Concentrations of Risk
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	The Company
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
	company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
	diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its
	capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina.
	The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop
	small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative
	cash flows from operations since inception.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Based on its current operating plans, the Company expects it has sufficient
	liquidity, with its existing cash, restricted cash and investments of $100,858, to continue its planned operations through mid-2017.
	The Company&rsquo;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product
	candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017
	it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts;
	(2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash
	milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional
	product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research
	and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities through private placement transactions
	or registered public offerings pursuant to a registration statement filed with the SEC.&nbsp;&nbsp;Additionally, the Company retains
	the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares,
	stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities
	and Exchange Commission (&ldquo;SEC&rdquo;) on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative
	cash flows until revenues reach a level sufficient to support ongoing operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Basis of Presentation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Beginning in March 2011, the consolidated financial statements include
	the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed
	in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 3, Royalty Monetization,
	for a further description of this transaction. All intercompany transactions and balances have been eliminated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company&#8217;s consolidated financial statements have been prepared
	in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Such consolidated financial
	statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects,
	the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than
	normal recurring adjustments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Reclassifications
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Long term deferred rent as of December 31, 2014 has been reclassified
	to conform to the 2015 presentation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Cash and Cash Equivalents
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company generally considers cash equivalents to be all cash held
	in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
	of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
	the short-term nature of these items.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Restricted Cash
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Restricted cash as of December 31, 2015 reflects $150 the Company
	is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program,
	$59 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes
	(defined in Note 3) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease
	execution and build-out of its new Birmingham research facilities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Investments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company invests in high credit quality investments in accordance
	with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
	policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
	requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
	agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
	debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
	municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
	investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
	and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
	risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
	this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
	need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
	interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
	has not realized any significant losses from its investments.
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company classifies all of its investments as available-for-sale.
	Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
	other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
	for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
	the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
	declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in
	the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
	recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
	at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
	the balance sheet date are classified as long-term. At December 31, 2015, the Company believes that the costs of its investments
	are recoverable in all material respects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The following tables summarize the fair value of the Company&#8217;s
	investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the
	fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
	prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
	that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amortized
<BR>
	Cost
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accrued
<BR>
	Interest
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Gross
<BR>
	Unrealized
<BR>
	Gains
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Gross
<BR>
	Unrealized
<BR>
	Losses
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Estimated
<BR>
	Fair Value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Obligations of U.S. Government and its agencies
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	26,557
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(99
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	26,546
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Corporate debt securities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,820
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	184
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(41
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,963
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	Certificates of deposit
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,884
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(72
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,838
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	70,261
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	293
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(212
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	70,347
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31, 2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amortized
<BR>
	Cost
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accrued
<BR>
	Interest
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Gross
<BR>
	Unrealized
<BR>
	Gains
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Gross
<BR>
	Unrealized
<BR>
	Losses
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Estimated
<BR>
	Fair Value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Obligations of U.S. Government and its agencies
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,307
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,306
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Corporate debt securities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,152
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	151
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(47
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,261
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Commercial paper
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,838
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(63
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,781
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59,297
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	179
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(133
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59,348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The following table summarizes the scheduled maturity for the Company&#8217;s
	investments at December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 67%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Maturing in one year or less
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22,664
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18,232
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Maturing after one year through two years
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,395
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,459
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Maturing after two years
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,288
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15,657
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	70,347
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59,348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Receivable from Collaborations
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Receivables from collaborations are recorded for amounts due to the
	Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables
	from Shionogi and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine
	if any reserve or allowance should be established at each reporting date. At December&nbsp;31, 2015 and 2014, the Company had the
	following receivables.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Billed
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Unbilled
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	U.S. Department of Health and Human Services
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,536
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,536
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Shionogi&nbsp;&amp; Co. Ltd.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	469
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	469
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Seqirus UK Limited
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	210
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	238
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total receivables
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	679
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,564
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,243
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31, 2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Billed
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Unbilled
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; WIDTH: 52%">
	U.S. Department of Health and Human Services
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,778
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,778
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Shionogi&nbsp;&amp; Co. Ltd.
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,071
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,071
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total receivables
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,071
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,778
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,849
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Monthly invoices are submitted to the U.S. Department of Health and
	Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
	indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
	are subject to audit by the U.S. Government.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Receivables from Product Sales
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	Receivables from product sales are recorded for amounts due to the
	Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established
	at each reporting date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Inventory
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	At December&nbsp;31, 2015 and 2014, the Company&rsquo;s inventory
	consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under
	the first-in, first-out (&ldquo;FIFO&rdquo;) method, or market. The Company expenses costs related to the production of inventories
	as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected
	to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize
	subsequent costs related to the production of inventories.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	During 2014, in connection with the FDA approval of RAPIVAB, the Company
	began capitalizing costs associated with the production of RAPIVAB inventories.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company&#8217;s inventory consisted of the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As of December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
<P STYLE="MARGIN: 0">
	Work in process
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,612
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	267
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Finished goods
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	416
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net inventories
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,612
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	683
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Property and equipment are recorded at cost. Depreciation is computed
	using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of
	three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures
	are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining
	lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded
	at its fair value, less depreciation. The building is being depreciated over a period of ten years equal to the term of the related
	lease
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In accordance with U.S. GAAP, the Company periodically reviews its
	property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets
	may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from
	the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
	the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed
	of are reported at the lower of carrying amount or fair value less cost to sell.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Patents and Licenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company seeks patent protection on all internally developed
	processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as
	recoverability of such expenditures is uncertain.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Accrued Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company generally enters into contractual agreements with third-party
	vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
	contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
	liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
	the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
	to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
	incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
	providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
	each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
	accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses
	include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to investigative sites in connection with clinical trials;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8226;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	professional fees.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company bases its expenses related to clinical trials on its
	estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that
	conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation,
	vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors
	such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
	estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
	timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	Accrued expenses were comprised of the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 67%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Compensation and benefits
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	424
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,105
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Development costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,398
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,232
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Inventory
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	549
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	397
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Professional fees
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	242
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	238
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Duties and taxes
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	102
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,522
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,282
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Total accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,237
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,329
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	As of December 31, 2015 and 2014, the carrying value of accrued
	expenses approximates their fair value due to their short-term settlement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Income Taxes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The liability method is used in the Company&#8217;s accounting for
	income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
	and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
	when the differences are expected to reverse.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Accumulated Other Comprehensive Loss
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Accumulated other comprehensive loss is comprised of unrealized gains
	and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified
	from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive
	Loss. During 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out
	of accumulated other comprehensive loss were recorded during 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company recognizes revenues from collaborative and other research
	and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable
	and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
	has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
	is reasonably assured.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<I>
	Collaborative and Other Research and Development Arrangements and Royalties
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Revenue from license fees, royalty payments, event payments, and
	research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
	performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
	under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
	by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
	of changes in the estimated revenue period are recognized prospectively.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Under certain of the Company&#8217;s license agreements, the Company
	receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
	when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	For arrangements that involve the delivery of more than one element,
	each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
	This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
	is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
	The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
	evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
	(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
	by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each
	deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered,
	limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables
	requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset,
	or another performance obligation.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In June 2015, the Company entered into a License Agreement (the &ldquo;SUL
	Agreement&rdquo;) granting Seqirus UK Limited (&ldquo;SUL&rdquo;) and its affiliates worldwide rights, excluding Israel, Japan,
	Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments,
	including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three
	deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&ldquo;EU&rdquo;)
	marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent
	upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to
	the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated
	to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately
	$1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support
	activities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Milestone payments are recognized as licensing revenue upon the achievement
	of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
	at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these
	revenue recognition criteria are recorded as deferred revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Under the terms of the SUL Agreement, the Company may receive up to
	$12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
	by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food
	Branch of Health Canada (&#8220;Health Canada&#8221;) for an adult indication in Canada. The Company evaluated each event based
	payment under the provisions of ASU 2010-17,
<I>
	Milestone Method of Revenue Recognition
</I>
	, and determined that each event based
	payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event
	based payments were achieved during the periods presented.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Reimbursements received for direct out-of-pocket expenses related
	to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
	reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
	the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
	Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<I>
	Product Sales
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company recognizes revenue for sales of RAPIVAB when title and
	substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment
	from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when
	there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability
	is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates.
	In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to
	physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL
	worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales,
	and the Company&rsquo;s commercial sales will be minimal.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Sales deductions consist of statutory rebates to state Medicaid, Medicare
	and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
	recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
	from historical experience adjusted to reflect known changes in the factors that impact such reserves.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company utilizes data from external sources to help it estimate
	gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes,
	but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through
	to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company accounts for these sales deductions in accordance with
	authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company has categorized and described more fully the following
	significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting
	estimates, and require it to use information from external sources.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 13.5PT">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 13.5PT">
<I>
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 13.5PT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 13.5PT">
<I>
	Rebates and Chargebacks
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Statutory rebates to state Medicaid agencies and Medicare are based
	on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
	on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under
	these programs relating to RAPIVAB sales.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Chargebacks claimed by specialty distributors are based on the
	differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid
	by eligible customers covered under federally qualified programs.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	The amount of the reserve for rebates and chargebacks is based
	on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
	experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
	and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through
	public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization
	data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions
	each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within
	nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional
	reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Discounts and Sales Incentives
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Discounts and other sales incentives primarily consist of Inventory
	Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the
	Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual
	contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of
	these fees by applying the contractual rates to such product sales.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Product Returns
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company does not record a product return allowance as it does
	not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company recorded the following revenues for the years ended December&nbsp;31:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 13.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Product sales, net
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,291
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Royalty revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,386
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,025
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,562
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Collaborative and other research and development revenues:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	U.S. Department of Health and Human Services
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,337
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,366
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,585
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Green Cross Corporation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Shionogi (Japan)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,184
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,184
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,184
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Seqirus UK Limited
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,927
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total collaborative and other research and development revenues
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39,580
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,769
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total revenues
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,257
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,608
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,331
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Advertising
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company engages in very limited distribution and direct-response
	advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Advertising and
	product promotion expenses were $103 and $290 for the years ended December&nbsp;31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The Company&#8217;s research and development costs are charged to
	expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
	of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
	future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
	goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
	costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
	and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
	manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
	by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
	on-going review of the level of services actually performed.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Additionally, the Company has license agreements with third parties,
	such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
	and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
	fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
	case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
	as incurred.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Deferred collaboration expenses represent sub-license payments, paid
	to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration
	paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred
	without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion
	to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with
	the associated revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	All share-based payments, including grants of stock option awards
	and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on
	their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value
	of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is
	recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
	performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Interest Expense and Deferred Financing Costs
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Interest expense for the years ended December&nbsp;31, 2015, 2014
	and 2013 was $5,200, $4,998 and $4,778, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly associated
	with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated Balance
	Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate
	method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&nbsp;31,
	2015, 2014 and 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Currency Hedge Agreement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In connection with the issuance by Royalty Sub of the PhaRMA Notes,
	the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
	yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to
	market adjustments are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market
	adjustments for the years ended December&nbsp;31, 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294,
	respectively. Mark to market adjustments are determined by a third party pricing model which uses quoted prices in markets that
	are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair
	value hierarchy as defined by U.S. GAAP. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related
	to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to
	post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2015 and December&nbsp;31,
	2014, no hedge collateral was posted under the agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Net Loss Per Share
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Net loss per share is based upon the weighted average number of common
	shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
	herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be
	issued under the Company&rsquo;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share
	for the years ended December&nbsp;31, 2015, 2014, and 2013 does not include 3,524, 3,991 and 1,430 respectively, of potential common
	shares as their impact would be anti-dilutive.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Use of Estimates
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The preparation of financial statements in conformity with U.S. GAAP
	requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
	could differ from those estimates.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 13.5PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 13.5PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 13.5PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 13.5PT; MARGIN: 0PT 0">
<B>
	Significant Customers and Other Risks
</B>
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 13.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
	Significant Customers
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Prior to the SUL Agreement, the Company relied primarily on three
	specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted
	for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&rsquo;s outstanding
	receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact
	the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent
	to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide
	basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will
	be made by the Company&rsquo;s partners and the Company will be reliant on these partners to generate sales and remit cash to
	satisfy receivables.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	The Company&#8217;s primary source of revenue that has an underlying
	cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with
	BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development
	costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the
	Company&#8217;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS
	peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#8217;s
	future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from
	the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest,
	and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of
	principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s
	drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform
	their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
	Risks from Third Party Manufacturing and Distribution Concentration
</I>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	The Company relies on single source manufacturers for active pharmaceutical
	ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays
	in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling
	of RAPIVAB.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
	Credit Risk
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Cash equivalents and investments are financial instruments which potentially
	subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess
	cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits.
	The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities
	that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio
	of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables
	discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which
	there is no assumed credit risk.
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;2&nbsp;&#8212; Property and Equipment
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	Property and equipment consisted of the following at December&nbsp;31:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 67%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Furniture and fixtures
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	718
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	542
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Office equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,122
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,115
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Software
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,427
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,423
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Laboratory equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,004
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,786
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Leased equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Leasehold improvements
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,610
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,303
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Construction in progress
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,821
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	Building
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,589
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,354
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,232
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Less accumulated depreciation and amortization
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,205
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,025
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Property and equipment, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,149
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	207
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Depreciation and amortization expense for the years ended December&nbsp;31,
	2015, 2014 and 2013 was $180, $177 and $304, respectively.
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note 3&#8212; Royalty Monetization
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 6PT">
<I>
	Overview
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
	transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
	licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received
	net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest
	reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account
	has been fully utilized with the September 2012 interest payment.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	As part of the transaction, the Company entered into a purchase and
	sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
	(i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
	right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
	Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi
	in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted
	as a result of this transaction.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 6PT">
<I>
	Non-Recourse Notes Payable
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	On March&nbsp;9, 2011, Royalty Sub completed a private placement to
	institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
	Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
	by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
	payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
	Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
	at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
	any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Royalty Sub&#8217;s obligations to pay principal and interest on
	the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
	to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
	may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
	pay any interest shortfall on, the PhaRMA Notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	In September&nbsp;2013, Royalty Sub paid $1,844 of interest on
	the PhaRMA Notes from royalty payments received from RAPIACTA
<SUP>
	&reg;
</SUP>
	sales from the preceding four calendar quarters.
	This payment resulted in an obligation shortfall of approximately $2,356 associated with accrued interest due September&nbsp;3,
	2013. As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to
	pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to
	the PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, the Company began accruing interest at 14%&nbsp;per
	annum on the interest shortfall of $2,356. In March, June and August of 2014, Royalty Sub paid additional interest of $446, $1,882
	and $70, respectively, bringing the 2013 shortfall down to $222 as of September 30, 2014. Under the terms of the Indenture, Royalty
	Sub&rsquo;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding Payment Date for
	the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related
	accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet. As a result of the event of
	default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the
	collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under
	the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments
	that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to
	the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the
	Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In
	addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be
	required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of
	Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact
	on the Company&rsquo;s future results of operations or cash flows. As of December 31, 2015, the PhaRMA Notes remain in default.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Indenture does not contain any financial covenants. The Indenture
	includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
	Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
	typical for indentures used in structured financings of this type.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, the aggregate fair value of the PhaRMA
	Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified
	as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The PhaRMA Notes are redeemable at the option of Royalty Sub at any
	time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
	interest through the redemption date on the PhaRMA Notes being redeemed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Foreign Currency Hedge
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In connection with the issuance by Royalty Sub of the PhaRMA Notes,
	the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
	yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen
	at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided
	the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
	the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Currency Hedge Agreement does not qualify for hedge accounting
	treatment; therefore mark to market adjustments are recognized in the Company&rsquo;s Consolidated Statement of Comprehensive
	Loss. Cumulative mark to market adjustments in 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294 respectively.
	In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese
	yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark
	to market adjustments based on defined thresholds. As of December&nbsp;31, 2015 and 2014, no collateral was posted under the Currency
	Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining
	payable under the Currency Hedge Agreement. As of December 31, 2015, the maximum amount of hedge collateral the Company may be
	required to post is $9,750.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;4&nbsp;&#8212; Lease Obligations and Other Contingencies
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company has the following minimum payments under operating lease
	obligations that existed at December&nbsp;31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	651
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	2017
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	871
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	2018
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	870
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	2019
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	820
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	2020
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	651
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	Thereafter
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,045
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total minimum payments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,908
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	The obligations in the preceding table are primarily related
	to the Company&rsquo;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&rsquo;s
	headquarters in Durham, North Carolina expires June&nbsp;30, 2020. The lease for the existing facility in Birmingham, Alabama currently
	expires on June&nbsp;30, 2016; however, in 2015, the Company leased an additional approximate 32,000 square feet in Birmingham
	to house its new research facility. The Company began construction on leasehold improvements for its new research facility in 2015
	and this lease obligates the Company for $4,839 of lease payments into 2027. Rent expense for operating leases was $664, $633,
	and $526 in 2015, 2014, and 2013, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 12PT 0 0">
<I>
	Lease Financing Obligation
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 12PT 0 0">
	Based on the terms of the lease agreement for the new research
	facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed
	the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset
	of $1,589, representing the Company&rsquo;s leased portion of the building and recorded a corresponding liability. Upon completion
	of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building
	asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected
	duration of the lease, and rental payments will be treated as principal and interest payments on the lease financing obligation
	liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease and
	or construction in process.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	At December 31, 2015, the lease financing obligation balance
	was $2,375 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments
	under the lease financing obligation are $4,839.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;5&nbsp;&#8212; Stockholders&#8217; Equity
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Sales of Common Stock
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	On March 3, 2015, the Company filed a $150,000 shelf registration
	statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell
	securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time
	to time at prices and on terms to be determined at the time of sale. The Company intends to file a post-effective amendment to
	this registration statement, which will allow for its use by the Company when declared effective by the SEC&rsquo;s staff.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration
	statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows us to
	sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from
	time to time at prices and on terms to be determined at the time of sale. On June 3, 2014, the Company issued 11,500 shares of
	common stock for gross proceeds of $115,000 under this $125,000 shelf registration statement. Net proceeds were approximately $107,800
	after deducting underwriting discounts and offering expenses. The Company has $10,000 remaining under this shelf registration statement
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	In August 2013, the Company completed a public offering of 4,600
	shares of its common stock at a price of $4.40 per share, which included the underwriters&#8217; over-allotment allocation of an
	additional 600 shares. Net proceeds were approximately $18,500 after deducting underwriting discounts and offering expenses. Shares
	of common stock in this offering were sold under the $70,000 shelf registration statement declared effective in July 2011.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	In June 2011, the Company entered into an At Market Issuance Sales
	Agreement (the &#8220;ATM Agreement&#8221;) with McNicoll, Lewis&nbsp;&amp; Vlak (&#8220;MLV&#8221;) pursuant to which the Company
	was able to sell $70,000 in shares of its common stock at current market prices under a Form S-3 registration statement with MLV
	acting as the sales agent. During 2012, the Company sold an aggregate of 4,516 shares of common stock at an average per share price
	of $4.08 pursuant to the ATM Agreement for net proceeds of $17,805. During 2013, the Company sold an aggregate of 2,883 shares
	of common stock at an average per share price of $1.85 pursuant to the Agreement for net proceeds of $5,218.
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;6&nbsp;&#8212; Stock-Based Compensation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 13.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Stock Incentive Plan
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, the Company had two stock-based employee
	compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
	both which were amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation
	expense of $9,705 ($9,485 of expense related to the Incentive Plan, $220 of expense related to the ESPP) was recognized during
	2015, while $10,177 ($9,963 of expense related to the Incentive Plan, $214 of expense related to the ESPP) was recognized during
	2014, and $4,368 ($4,253 of expense related to the Incentive Plan, $115 of expense related to the ESPP) was recognized during 2013.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	The Company accounts for stock-based compensation in accordance
	with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 24.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December&nbsp;31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,580
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,906
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,664
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,125
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,271
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	704
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,705
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,177
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,368
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company grants stock option awards and restricted stock unit
	awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are
	granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing March&nbsp;1,
	2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013,
	the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully
	vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively.
	These awards vest upon successful completion of specific development milestones. As of December 31, 2015, 75% of the August 2013
	grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which
	vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of
	2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered
	BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of December&nbsp;31, 2015, 25%
	of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation
	expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to
	non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5
	to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in
	the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive
	Plan.
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Related activity under the Incentive Plan is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Awards
<BR>
	Available
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
<BR>
	Outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT">
	Balance at December&nbsp;31, 2012
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,815
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,073
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.09
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(310
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock awards cancelled
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock option awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3,277
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,277
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock option awards exercised
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(563
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.37
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Stock option awards cancelled
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,801
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,801
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.22
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Balance at December&nbsp;31, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,082
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,986
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.99
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Plan amendment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,750
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(593
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock awards cancelled
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock option awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,965
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,965
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10.99
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock option awards exercised
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,258
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.78
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Stock option awards cancelled
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(88
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.83
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Balance at December&nbsp;31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,362
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,605
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.21
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(163
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock awards cancelled
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock option awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,217
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,217
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11.52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock option awards exercised
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,118
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.36
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Stock option awards cancelled
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(33
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.87
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Balance at December&nbsp;31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,671
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.50
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	For stock option awards granted under the Incentive Plan during
	2015, 2014 and 2013, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions
	noted in the table below. The weighted average grant date fair value of these awards granted during 2015, 2014 and 2013 was $7.72,
	$8.02, and $1.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using
	a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the
	stock option awards granted during 2015, 2014, and 2013. The expected life is based on the average of the assumption that all outstanding
	stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised
	at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The
	expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has
	assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future.
	The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining
	term equal to the expected term.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Weighted Average Assumptions for Stock Option Awards Granted under the
	Incentive Plan
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected Life
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.7
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected Volatility
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	87
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected Dividend Yield
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Risk-Free Interest Rate
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.7
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The total intrinsic value of stock option awards exercised under the
	Incentive Plan was $10,117 during 2015, $8,522 during 2014, $738 and during 2013. The intrinsic value represents the total proceeds
	(fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received
	by all individuals who exercised stock option awards during the period.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The following table summarizes, at December&nbsp;31, 2015, by price
	range: (1)&nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their
	weighted average remaining life and their weighted average exercise price; and (2)&nbsp;for stock option awards exercisable under
	the Plan, the number of stock option awards exercisable and their weighted average exercise price:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="9" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Exercisable
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	Range
</U>
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Number
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Weighted
<BR>
	Average
<BR>
	Remaining
<BR>
	Life
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Weighted
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Number
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Weighted
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	$
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	0
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	3
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,826
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.4
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.51
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,322
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.55
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,792
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.1
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.63
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,329
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.53
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	9
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,153
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.10
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,070
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.13
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	9
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	12
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,728
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8.1
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	11.07
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	714
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	11.45
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	12
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	15
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,077
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.4
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12.44
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	374
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12.65
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	15
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	18
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1.1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	95
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.5
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15.39
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8212;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8212;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	$
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	0
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	to
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	18
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.25PT; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	10,671
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.7
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.50
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,809
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.70
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The weighted average remaining contractual life of stock option
	awards exercisable under the Incentive Plan at December&nbsp;31, 2015 was 5.0 years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The aggregate intrinsic value of stock option awards outstanding
	and exercisable under the Incentive Plan at December&nbsp;31, 2015 was $28,511. The aggregate intrinsic value represents the value
	(the period&#8217;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would
	have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the
	end of the year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The total fair value of the stock option awards vested under the
	Incentive Plan was $4,492 during 2015, $2,844 during 2014, and $3,483 during 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, the number of stock option awards
	vested and expected to vest under the Incentive Plan is 9,633. The weighted average exercise price of these stock option awards
	is $7.51 and their weighted average remaining contractual life is 6.6&nbsp;years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The following table summarizes the changes in the number and weighted-average
	grant-date fair value of non-vested stock option awards during 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Non-Vested
<BR>
	Stock Option
<BR>
	Awards
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted Average
<BR>
	Grant-Date Fair
<BR>
	Value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 67%; FONT-SIZE: 10PT">
	Balance December&nbsp;31, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,385
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.27
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stock option awards granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,217
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.72
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stock option awards vested
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,711
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.63
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Stock option awards forfeited
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.39
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Balance December&nbsp;31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,863
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.40
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, there was approximately $18,607 of total
	unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company.
	That cost is expected to be recognized as follows: $7,023 in 2016, $6,010 in 2017, $3,891 in 2018, and $1,683 in 2019.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<B>
<I>
	Employee Stock Purchase Plan
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The Company has reserved a total of 1,475&nbsp;shares of common stock
	to be purchased under the ESPP, of which 497&nbsp;shares remain available for purchase at December&nbsp;31, 2015. Eligible employees
	may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price
	during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates
	and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	There were 41, 49 and 89 shares of common stock purchased under the
	ESPP in 2015, 2014, and 2013, respectively, at a weighted average price per share of $8.65, $6.29, and $1.39, respectively. Expense
	of $220, $214, and $115, related to the ESPP was recognized during 2015, 2014, and 2013, respectively. Compensation expense for
	shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a
	Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during 2015, 2014,
	and 2013, were $4.93, $4.41, and $1.27, respectively.&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Note&nbsp;7&nbsp;&#8212; Income Taxes
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company has incurred net losses since inception and, consequently,
	has not recorded any U.S.&nbsp;Federal and state income tax expense or benefit. The differences between the Company&#8217;s effective
	tax rate and the statutory tax rate in 2015, 2014, and 2013 are as follows:
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Income tax benefit at federal statutory rate (35%)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(15,057
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(15,816
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,538
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	State and local income taxes net of federal tax benefit
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(819
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,286
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(839
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Permanent items
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	560
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	258
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	738
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Rate change
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,012
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,892
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expiration of attribute carryforwards
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	373
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	242
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Research and development tax credits
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,454
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(748
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,206
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Orphan drug credit
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,307
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(218
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(115
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,144
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,339
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,312
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,567
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Income tax expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company recognizes the impact of a tax position in its financial
	statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position.
	The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit
	carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and
	the best estimate of the underlying credit. Any changes to the Company&rsquo;s unrecognized tax benefits are offset by an adjustment
	to the valuation allowance and there would be no impact on the Company&rsquo;s financial statements. The Company does not expect
	its unrecognized tax benefits to change significantly over the next 12 months.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	A reconciliation of the beginning and ending amount of unrecognized
	tax benefits is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT">
	Balance at January&nbsp;1,
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	472
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	284
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Additions to current period tax positions
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,616
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	176
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Additions to prior period tax positions
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Reductions to prior period tax provisions
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Balance at December&nbsp;31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,085
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	472
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The Company&rsquo;s ability
	to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the
	event of past or future ownership changes as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended and similar
	state tax law.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Significant components of the Company&#8217;s deferred tax assets
	and liabilities are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred tax assets:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net federal and state operating losses
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	142,836
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	135,922
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development credits
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,551
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38,096
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Fixed assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,054
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,073
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Deferred revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,240
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,798
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,605
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,086
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,590
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,178
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total deferred tax assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	207,876
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	187,153
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred tax liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Foreign currency derivative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,668
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total deferred tax liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,668
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(205,208
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(184,868
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net deferred tax assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The majority of the Company&rsquo;s deferred tax assets relate
	to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future
	periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company
	has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization.
	The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related
	tax benefits will be realized. The Company&rsquo;s valuation allowance increased by $20,339 in 2015, $17,312 in 2014, and $8,567
	in 2013.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	As of December&nbsp;31, 2015, the Company had federal operating
	loss carryforwards of $386,219, state operating loss carryforwards of $373,454, and research and development and orphan drug credit
	carryforwards of $48,551, which will expire at various dates from 2016 through 2035. The federal losses begin to expire in 2018,
	the state losses begin to expire in 2016 and the research and development contracts begin to expire in 2018.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company&rsquo;s federal and state operating loss carryforwards
	include $15,655 of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions
	has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments
	to additional paid-in capital.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	Tax years 2012-2014 remain open to examination by the major taxing
	jurisdictions to which the Company is subject. Additionally, years prior to 2012 are also open to examination to the extent of
	loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax
	benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in
	2015, 2014, and 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;8&nbsp;&#8212; Employee 401(k) Plan
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In January 1991, the Company adopted an employee retirement plan (&#8220;401(k)
	Plan&#8221;) under Section&nbsp;401(k) of the Internal Revenue Code covering all employees. Employee contributions may be made
	to the 401(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions may be made at the
	discretion of the Board of Directors. The Company made matching contributions of $366, $361, and $313, in 2015, 2014, and 2013,
	respectively.
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;9&nbsp;&#8212; Collaborative and Other Research and Development
	Contracts
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
	U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).
</I>
	In January 2007, the U.S.&nbsp;Department of Health and Human Services (&ldquo;BARDA/HHS&rdquo;) awarded the Company a $102,661,
	four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development
	shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract
	modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&nbsp;24, 2011, the
	Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development
	of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract
	award from BARDA/HHS to $234,852 and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir
	in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December
	2014. The BARDA/HHS contract expired on June 30, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	On March 31, 2015, the Company announced that the Biomedical Research
	and Development Authority within the U.S. Department of Health and Human Services&rsquo; Office of the Assistant Secretary for
	Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases
	caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430
	drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the
	potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options
	within this contract.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
	National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;).
</I>
	In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease.
	NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this
	contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period.
	The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the
	treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human
	clinical trial. As of December 31, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430
	is the lead compound in the Company&#8217;s BSAV research program.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
	contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
	that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic
	assessments of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality
	of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These
	contracts are terminable by the government at any time for breach or without cause.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
<I>
	Seqirus UK Limited (&#8220;SUL&#8221;).
</I>
	On June 16, 2015,
	the Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary
	of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement")
	granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
	treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
	together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
	currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
	in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated
	influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and
	associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue
	government stockpiling outside the U.S.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27.35PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
	subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
	SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
	of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In December 2013, the Company submitted a New Drug Application ("NDA")
	for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval
	commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility
	for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory
	filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for
	RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee,
	composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the
	commercialization of RAPIVAB in the Territory and any additional development.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Under the terms of the SUL Agreement, the Company received an upfront
	payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory
	milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in
	the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive
	tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
	as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the
	Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
	Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
	Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
	impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
	on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
	the date of the SUL Agreement (the "Royalty Term"). The Company developed RAPIVAB under a license from UAB and will owe
	sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
<I>
	Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).
</I>
	In
	February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
	Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
	obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
	will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
	October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
	Taiwan. Shionogi has commercially launched
	peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
	Green Cross Corporation (&#8220;Green Cross&#8221;).
</I>
	In
	June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms
	of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company
	received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale
	of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross
	will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products
	in Korea.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
	Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).
</I>
	In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
	and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology (the
	&#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets
	across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Company deferred revenue recognition of the $10,000 up-front
	payment that was received from Mundipharma in February&nbsp;2006 because the Company was involved in the continued development
	of forodesine. Amortization of this revenue commenced in February&nbsp;2006 and was initially scheduled to end in October&nbsp;2017,
	which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition
	of a $5,000 payment received from Mundipharma in connection with the initiation of a clinical trial in 2007. Amortization of this
	deferred revenue commenced in 2007 and was initially scheduled to end in October&nbsp;2017. Under its agreement with AECOM/IRL,
	the Company paid sublicense payments related to these upfront cash payments received from Mundipharma. Expense recognition of these
	sublicense payments was deferred and recognized under the same term as the related deferred revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	On November&nbsp;11, 2011, the Company entered into the Amended
	and Restated License and Development Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Mundipharma, amending and
	restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights
	to forodesine. Commencing on November&nbsp;11, 2011, Mundipharma controls the development and commercialization of forodesine and
	assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of
	future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging
	from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties
	are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in
	each country.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	The Amended and Restated Agreement is a multiple element arrangement
	for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in
	the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine
	(the &ldquo;Knowledge Transfer&rdquo;). The Company accounted for these elements as a combined unit of accounting as they do not
	have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on November&nbsp;11, 2011 and the
	Knowledge Transfer was completed during the first quarter of 2012.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
<I>
	Albert Einstein College of Medicine of Yeshiva University and Industrial
	Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).
</I>
	In June 2000, the Company licensed a series of potent
	inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
	are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
	any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
	to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
	reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
	product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
	single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
	payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
	can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
	may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
	the Licensors.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	In May 2010, the Company amended the licensee agreement through which
	the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
	research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
	to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
	PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
	may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
	from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
	The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In consideration for these modifications in 2010, the Company issued
	to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally,
	at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid
	by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination
	of cash and shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	On November&nbsp;17, 2011, the Company further amended its agreements
	with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined)
	received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	On June&nbsp;19, 2012, the Company further amended its agreements
	with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
	exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	At its sole option and subject to certain agreed upon conditions,
	any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash,
	in shares of the Company&#8217;s common stock, or in a combination of cash and shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	On January 6, 2014, the Carbohydrate Chemistry Research Team from
	Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;)
	to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts
	relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst
	is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties,
	the terms and conditions of the contracts are substantially the same
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
<I>
	The University of Alabama at Birmingham (&#8220;UAB&#8221;).
</I>
	The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
	UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
	rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
	has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
	third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
	terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
	upon three months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
	parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
	resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
	but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
	products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;10&nbsp;&#8212; Quarterly Financial Information (Unaudited)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	First
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Second
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Third
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fourth
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015 Quarters
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Revenues
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,826
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,842
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,987
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,602
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net (Loss) Income
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(15,164
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,901
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,621
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18,135
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Basic net (loss) income per share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.21
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.07
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Diluted net (loss) income per share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.21
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014 Quarters
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Revenues
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,458
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,466
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,238
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,446
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net Loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,137
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,649
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(8,731
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,672
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	&nbsp;
</B>
</P>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0PT">
<B>
	Note&nbsp;11&nbsp;&#8212; Recent Accounting Pronouncements
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	In November 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
	issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-17,
<I>
	Balance Sheet Classification of Deferred Taxes
</I>
	, requiring
	all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet.
	The classification change for all deferred taxes as noncurrent simplifies entities&#8217; processes as it eliminates the need to
	separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation
	allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption
	of this standard had no impact on the Company&#8217;s consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.3PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In April 2015, the FASB issued ASU No.2015-03,
<I>
	Simplifying the
	Presentation of Debt Issuance Costs
</I>
	. This standard amends existing guidance to require the presentation of debt issuance costs
	in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is
	effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect
	this standard will have a material impact on its consolidated financial statements.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
	BIOCRYST PHARMACEUTICALS, INC.
<BR>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(In thousands, except per share amounts)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In August 2014, the FASB issued ASU No. 2014-15 &#8211;
<I>
	Presentation
	of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue
	as a Going Concern,
</I>
	which defines management&#8217;s responsibility to evaluate, at each annual and interim reporting period,
	whether there are conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going concern
	within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances.
	In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#8217;s
	ability to continue as a going concern within one year after the issuance date.&nbsp; Disclosures are required if conditions give
	rise to substantial doubt.&nbsp;This standard is effective for all companies in the first annual period ending after December 15,
	2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard
	will have on its financial statements and disclosures.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	In May 2014, the FASB issued ASU 2014-09 &ndash;
<I>
	Revenue from
	Contracts with Customers
</I>
	, which provides a single, comprehensive revenue recognition model for all contracts with customers.
	The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers
	in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
	This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising
	from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to
	obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which
	will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January
	1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method.
	The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 22.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_022616P_HTM_A_017">
</A>
	Report of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	The Board of Directors and Stockholders
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	BioCryst Pharmaceuticals, Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We have audited the consolidated balance sheets of BioCryst Pharmaceuticals,
	Inc. as of December 31, 2015 and 2014, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity
	and cash flows for each of the three years in the period ended December&nbsp;31, 2015. These financial statements are the responsibility
	of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We conducted our audits in accordance with the standards of the Public
	Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
	assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
	evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
	used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
	that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In our opinion, the financial statements referred to above present
	fairly, in all material respects, the consolidated financial position of BioCryst Pharmaceuticals, Inc. at December&nbsp;31, 2015
	and 2014, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31,
	2015, in conformity with U.S.&nbsp;generally accepted accounting principles.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We also have audited, in accordance with the standards of the Public
	Company Accounting Oversight Board (United States), BioCryst Pharmaceuticals, Inc.&rsquo;s internal control over financial reporting
	as of December&nbsp;31, 2015, based on criteria established in
<I>
	Internal Control-Integrated Framework
</I>
	issued by the Committee
	of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February 26, 2016 expressed an unqualified
	opinion thereon.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%">
	/s/&nbsp;Ernst&nbsp;&amp; Young LLP
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Raleigh, North Carolina
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	February 26, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<A NAME="F10K_022616P_HTM_A_018">
</A>
<B>
	Report of Independent Registered Public Accounting
	Firm
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	The Board of Directors and Stockholders
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	BioCryst Pharmaceuticals, Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We have audited BioCryst Pharmaceuticals, Inc.&#8217;s internal control
	over financial reporting as of December&nbsp;31, 2015, based on criteria established in
<I>
	Internal Control-Integrated Framework
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO criteria). BioCryst Pharmaceuticals,
	Inc.&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment
	of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal
	Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial
	reporting based on our audit.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We conducted our audit in accordance with the standards of the Public
	Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
	assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit
	included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists,
	testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such
	other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
	opinion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	A company&#8217;s internal control over financial reporting is a process
	designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
	for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial
	reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail,
	accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance
	that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
	accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
	of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection
	of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial
	statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Because of its inherent limitations, internal control over financial
	reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
	to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
	or procedures may deteriorate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	In our opinion, BioCryst Pharmaceuticals, Inc. maintained, in all
	material respects, effective internal control over financial reporting as of December&nbsp;31, 2015, based on the COSO criteria.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We also have audited, in accordance with the standards of the Public
	Company Accounting Oversight Board (United States), the consolidated balance sheets of BioCryst Pharmaceuticals, Inc. as of December&nbsp;31,
	2015 and 2014, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for each
	of the three years in the period ended December&nbsp;31, 2015 of BioCryst Pharmaceuticals, Inc. and our report dated February 26,
	2016 expressed an unqualified opinion thereon.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%">
	/s/&nbsp;Ernst&nbsp;&amp; Young LLP
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Raleigh, North Carolina
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	February 26, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<A NAME="F10K_022616P_HTM_A_019">
</A>
<B>
	ITEM&nbsp;9.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 6PT">
	None.
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 6PT">
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_020">
</A>
	ITEM&nbsp;9A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	CONTROLS AND PROCEDURES
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 4.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
<B>
	Evaluation of Disclosure Controls and Procedures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 4.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	We maintain a set of disclosure controls and procedures that are designed
	to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
	Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized and reported in
	a timely manner under the Exchange Act of 1934. We carried out an evaluation as required by paragraph (b)&nbsp;of Rule&nbsp;13a-15
	or Rule&nbsp;15d-15 under the Exchange Act, under the supervision and with the participation of management, including our Chief
	Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and
	procedures (as defined in Rule&nbsp;13a-15(e) or Rule&nbsp;15d-15 under the Exchange Act). Based upon that evaluation, the Chief
	Executive Officer and Chief Financial Officer concluded that, as of December&nbsp;31, 2014, our disclosure controls and procedures
	are effective. We believe that our disclosure controls and procedures will ensure that information required to be disclosed in
	the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods
	specified in the rules and forms of the Securities and Exchange Commission, and include controls and procedures designed to ensure
	that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our
	Chairman and Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
<B>
	Management&#8217;s Report on Internal Control Over Financial Reporting
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 4.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Management of BioCryst Pharmaceuticals, Inc. is responsible for establishing
	and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control
	over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a
	process designed by, or under the supervision of our principal executive and principal financial officers and effected by our Board
	of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
	and the preparation of the financial statements in accordance with U.S.&nbsp;GAAP.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Our internal control over financial reporting is supported by written
	policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
	our transactions and dispositions of our assets; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary
	to permit preparation of the financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being
	made only in accordance with authorizations of our management and directors; and (3)&nbsp;provide reasonable assurance regarding
	prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect
	on the financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Because of its inherent limitations, internal control over financial
	reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
	to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
	or procedures may deteriorate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	In connection with the preparation of our annual financial statements,
	management has undertaken an assessment of the effectiveness of our internal control over financial reporting as of December&nbsp;31,
	2015, based on criteria established in Internal Control&nbsp;&#8212; Integrated Framework issued by the Committee of Sponsoring
	Organizations of the Treadway Commission (2013 Framework) (the COSO Framework). Management&#8217;s assessment included an evaluation
	of the design of our internal control over financial reporting and testing of the operational effectiveness of those controls.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23.05PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Based on this assessment, management has concluded that as of December&nbsp;31,
	2015, our internal control over financial reporting was effective. Management believes our internal control over financial reporting
	will provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
	for external purposes in accordance with U.S. GAAP.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Ernst&nbsp;&amp; Young LLP, the independent registered public accounting firm that audited our financial
	statements included in this report, has issued an attestation report on the Company&rsquo;s internal control over financial reporting,
	a copy of which appears on page&nbsp;80 of this annual report.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Changes in Internal Control over Financial Reporting
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	There have been no changes in our internal control over financial
	reporting that occurred during the quarter ended December&nbsp;31, 2015 that have materially affected, or are reasonably likely
	to materially affect, our internal control over financial reporting.&nbsp;
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_021">
</A>
	ITEM&nbsp;9B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	OTHER INFORMATION
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 6PT">
	None.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PART&nbsp;III
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_022">
</A>
	ITEM&nbsp;10.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The information required by this item is set forth under the captions
<I>
	&#8220;Items to be Voted on&nbsp;&#8212; 1. Election of Directors,&#8221; &#8220;Executive Officers,&#8221; &#8220;Section&nbsp;16(a)
	Beneficial Ownership Reporting Compliance&#8221;
</I>
	and
<I>
	&#8220;Corporate Governance&#8221;
</I>
	in our definitive Proxy Statement
	for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_023">
</A>
	ITEM&nbsp;11.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	EXECUTIVE COMPENSATION
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The information required by this item is set forth under the captions
<I>
	&#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;Grants of Plan-Based Awards
	in 2015,&#8221; &#8220;Outstanding Equity Awards at December&nbsp;31, 2015,&#8221; &#8220;2015 Option Exercises and Stock Vested,&#8221;
	&#8220;Potential Payments Upon Termination or Change in Control,&#8221; &#8220;2015 Director Compensation,&#8221; &#8220;Compensation
	Committee Interlocks and Insider Participation&#8221;
</I>
	and
<I>
	&#8220;Compensation Committee Report&#8221;
</I>
	in our definitive
	Proxy Statement for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.&nbsp;
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_024">
</A>
	ITEM&nbsp;12.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The information required by this item is set forth under the captions
<I>
	&#8220;Equity Compensation Plan Information&#8221;
</I>
	and &#8220;
<I>
	Security Ownership of Certain Beneficial Owners and Management&#8221;
</I>
	in our definitive Proxy Statement for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_025">
</A>
	ITEM&nbsp;13.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The information required by this item is set forth under the captions
<I>
	&#8220;Certain Relationships and Related Transactions&#8221;
</I>
	and &#8220;
<I>
	Corporate Governance&#8221;
</I>
	in our definitive
	Proxy Statement for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_026">
</A>
	ITEM&nbsp;14.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	PRINCIPAL ACCOUNTING FEES AND SERVICES
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	The information required by this item is set forth under the caption
<I>
	&#8220;2. Ratification of Appointment of Independent Registered Public Accountants&#8221;
</I>
	in our definitive Proxy Statement
	for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PART&nbsp;IV
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="F10K_022616P_HTM_A_027">
</A>
	ITEM&nbsp;15.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; PADDING-TOP: 12PT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	EXHIBITS, FINANCIAL STATEMENT SCHEDULES
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
<I>
	(a)&nbsp;Financial Statements
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 11.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	The following financial statements appear in Item&nbsp;8 of this Form&nbsp;10-K:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Page&nbsp;in
<BR>
	Form&nbsp;10-K
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_012">
	Consolidated Balance Sheets at December&nbsp;31, 2015 and 2014
</A>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_012">
	54
</A>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_013">
	Consolidated Statements of Comprehensive Loss for the years ended December&nbsp;31, 2015, 2014 and 2013
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_013">
	55
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_014">
	Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2015, 2014 and 2013
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_014">
	56
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_015">
	Consolidated Statements of Stockholders&#8217; Equity for the years ended December&nbsp;31, 2015, 2014 and 2013
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_015">
	57
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_016">
	Notes to Consolidated Financial Statements
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_016">
	58
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_017">
	Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_017">
	79
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<A HREF="#F10K_022616P_HTM_A_018">
	Report of Independent Registered Public Accounting Firm on Internal Control
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<A HREF="#F10K_022616P_HTM_A_018">
	80
</A>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	No financial statement schedules are included because the information
	is either provided in the consolidated financial statements or is not required under the related instructions or is inapplicable
	and such schedules therefore have been omitted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
	(b)&nbsp;
<I>
	Exhibits.
</I>
	See Index of Exhibits.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<A NAME="F10K_022616P_HTM_A_028">
</A>
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities
	Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
	authorized on February 26, 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2">
	BIOCRYST PHARMACEUTICALS, INC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	By:
</TD>
<TD STYLE="WIDTH: 29%; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Jon P. Stonehouse
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Jon P. Stonehouse
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<I>
	Chief Executive Officer
</I>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
	Pursuant to the requirements of the Securities Exchange Act
	of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated
	on February 26, 2016:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	Signature
</U>
</B>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<B>
<U>
	Title(s)
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Jon P. Stonehouse
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	President, Chief Executive Officer and Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Jon P. Stonehouse)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	(Principal Executive Officer)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Thomas R. Staab II
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Senior Vice President, Chief Financial Officer and Treasurer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Thomas R. Staab II)
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Principal Financial Officer and Principal Accounting Officer)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ George B. Abercrombie
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(George B. Abercrombie)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Fred E. Cohen
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Fred E. Cohen, M.D., D. Phil)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Stanley C. Erck
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Stanley C. Erck)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Nancy Hutson
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Nancy Hutson, Ph.D.)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Robert A. Ingram
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Robert A. Ingram)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Kenneth B. Lee, Jr.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Kenneth B. Lee, Jr.)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Sanj K. Patel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Sanj K. Patel)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Charles A. Sanders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	(Charles A. Sanders,&nbsp;M.D.)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0PT 0 0PT 12PT">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 12PT 0 0">
<B>
<A NAME="F10K_022616P_HTM_A_029">
</A>
	INDEX TO EXHIBITS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0.8PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<B>
<U>
	Number
</U>
</B>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<B>
<U>
	Description
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed December 22, 2006.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed July 24, 2007.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	3.3
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed May 8, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	3.4
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed November 4, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	3.5
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed May 8, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	3.6
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed November 4, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Indenture, dated as of March 9, 2011 by and between JPR Royalty Sub LLC and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Form 10-Q filed May&nbsp;6, 2011.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.1&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Stock Incentive Plan dated March 29, 2012. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K, filed May 25, 2012.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.2&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Stock Incentive Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed May 5, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.3&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Employee Stock Purchase Plan dated March 29, 2012. Incorporated by reference to the Company&#8217;s Form 8-K, filed May 25, 2012.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.4&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Employee Stock Purchase Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed May 5, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.5
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Notice of Grant of Non-Employee Director Automatic Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 10-K filed March 4, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.6&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Notice of Grant of Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.5 of the Company&#8217;s Form 10-K filed March 4, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.7&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Notice of Grant of Stock Option and Stock Option Agreement.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.7 of the Company&#8217;s Form 10-K filed March 2, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.8&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.8 of the Company&#8217;s Form 10-K filed March 2, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.9&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Annual Incentive Plan. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed March 12, 2012.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.10&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Relocation Policy. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form&nbsp;10-K filed March 4, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.11&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Employment Letter Agreement dated February 14, 2007, by and between the Company and Jon P. Stonehouse. Incorporated by reference to Exhibit 10.12 to the Company&#8217;s Form 10-K for the year ended December 31, 2006, filed March 14, 2007.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.12&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Thomas R. Staab II, dated May 23, 2011. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed May 25, 2011.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.13&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan dated June 12, 2008. Incorporated by reference to Exhibit 10.27 of the Company&#8217;s Form 10-Q filed August 8, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.14&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Yarlagadda S. Babu dated April 27, 2012.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.15&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Alane P. Barnes dated August 8, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.16&amp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Lynne Powell dated December 30, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form 10-K filed March 2, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.17#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Agreement dated January 3, 2007, between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, as amended by Amendment number 1 dated January 3, 2007 and Amendment number 2 dated May 11, 2007. Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed August 9, 2007. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.18
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, dated October 2, 2007. Incorporated by reference to Exhibit 10.6 of the Company&#8217;s Form 10-K filed March 4, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated April 3, 2008. Incorporated by reference to Exhibit 10.29 of the Company&#8217;s Form 10-Q filed August 8, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.20
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated July 2, 2008. Incorporated by reference to Exhibit 10.30 of the Company&#8217;s Form 10-Q filed August 8, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated August&nbsp;18, 2008. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed November&nbsp;7, 2008.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.22
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #7 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated November&nbsp;17, 2008. Incorporated by reference to Exhibit 10.12 of the Company&#8217;s Form 10-K filed March&nbsp;6, 2009.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.23
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated March 13, 2009. Incorporated by reference to Exhibit&nbsp;10.13 of the Company&#8217;s Form 10-K filed March 9, 2010.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.24
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated September 18, 2009. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed November 6, 2009.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.25
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #10 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated October 15, 2009. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed November 6, 2009.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.26
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #11 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 23, 2011. Incorporated by reference to Exhibit 10.25 of the Company&#8217;s Form 10-K filed March 15, 2011.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.27
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Stop-Work Order from U.S. Department of Health and Human Services, dated March 26, 2013, relating to Agreement dated January 3, 2007 between the Company and the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed May 9, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.28
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #13 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 15, 2012.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.29
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #14 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated June 4, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed June 5, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.30#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #15 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated September 5, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed November 8, 2013. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.31
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #16 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated December 17, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed December 23, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.32
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #17 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 21, 2014. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed February 26, 2014.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.33
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Order for Supplies or Services from the U.S. Department of Health &amp; Human Services, dated November 4, 2009. Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form 10-K filed March 9, 2010.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.34
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #18 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated March 28, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed April 3, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.35
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated April 29, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed May 2, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.36
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #20 to the Agreement to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated May 30, 2014. . Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed June 5, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.37#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	License, Development and Commercialization Agreement dated as of February 28, 2007, by and between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed May 10, 2007. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.38#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	First Amendment to License, Development and Commercialization Agreement, effective as of September 30, 2008, between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.19 to the Company&#8217;s Form 10-K filed March 6, 2009. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.39
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Riverchase Business Park Warehouse Lease dated July 12, 2000 between RBP, LLC an Alabama Limited Liability Company and the Registrant for office/warehouse space. Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form 10-Q for the second quarter ending June 30, 2000 filed August 8, 2000.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.40
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Third Amendment to Lease Agreement dated August 7, 2007, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 10-Q filed August 9, 2007.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.41
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Fourth Amendment to the Lease Agreement dated February 1, 2012, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.27 of the Company&#8217;s Form 10-K filed March 11, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.42
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Fifth Amendment to Lease Agreement dated January 15, 2015, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.42 of the Company&#8217;s Form 10-K filed March 2, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.43
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Stock and Warrant Purchase Agreement dated as of August 6, 2007, by and among BioCryst Pharmaceuticals, Inc. and each of the Investors identified on the signature pages thereto. Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Form 8-K filed August 7, 2007.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.44
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Stock Purchase Agreement, dated as of February&nbsp;17, 2005, by and among BioCryst Pharmaceuticals, Inc., Baker Bros. Investments, L.P., Baker Biotech Fund II, L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund&nbsp;II (Z), L.P., Baker/Tisch Investments, L.P., Baker Biotech Fund III, L.P., Baker Biotech Fund&nbsp;I, L.P., Baker Biotech Fund&nbsp;III (Z), L.P. and 14159, L.P. Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed February&nbsp;17, 2005.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.45#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Development and License Agreement dated as of February 1, 2006, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Holdings Limited. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K/A filed May 2, 2006. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.46#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Development and License Agreement, dated as of November 11, 2011, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Corporation Limited. Incorporated by reference to Exhibit 10.32 to the Company&#8217;s Form 10-K filed March 6, 2012. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.47#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second Amendment Agreement dated as of April 15, 2005. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed November 30, 2005. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.48#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Third Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of December&nbsp;11, 2009. Incorporated by reference to Exhibit 10.33 to the Company&#8217;s Form 10-K filed March&nbsp;9, 2010. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.49#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Fourth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of May 5, 2010. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed August 6, 2010. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.50#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Fifth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of November 17, 2011. Incorporated by reference to Exhibit 10.36 to the Company&#8217;s Form 10-K filed March 6, 2012. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.51#
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Sixth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of June 19, 2012. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed August 8, 2012. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.52
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Mundipharma International Corporation Limited, Callaghan Innovation Research Limited, and Victoria Link Limited, dated May 18, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form 10-Q filed August 7, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.53
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Callaghan Innovation Research Limited, and Victoria Link Limited, dated June 24, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Form 10-Q filed August 7, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.54
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Purchase and Sale Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and JPR Royalty Sub LLC. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed May 6, 2011.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.55
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Pledge and Security Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed May 6, 2011.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.56
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Confirmation of terms and conditions of ISDA Master Agreement, dated as of March 7, 2011, between Morgan Stanley Capital Services Inc. and BioCryst Pharmaceuticals, Inc. dated as of March 9, 2011. Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 10-Q filed May 6, 2011.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.57#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Agreement, dated as of September&nbsp;12, 2013, between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed November&nbsp;8, 2013. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.58#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 26, 2013.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.51 to the Company&#8217;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.59#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated January 24, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.52 to the Company&#8217;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.60#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.61#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.61#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 11, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.62#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 27, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.63#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 17, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.64#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 29, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.65#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #10 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated February 13, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.66#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #11 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 19, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.67#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #12 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 12, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.68#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #13 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.69#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 16, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(10.70)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #15 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated November 16, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(10.71)&#8224;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #16 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 18, 2015. (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.72#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, dated March 27, 2015. &nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on May 8, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.73#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated June 2, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.74#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated July 8, 2015. &nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.75#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated August 25, 2015. &nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.76#
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement by and between BioCryst Pharmaceuticals, Inc. and Seqirus UK Limited, dated as of June 16, 2015. &nbsp;Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form 10-Q filed on May 8, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(21)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Subsidiaries of the Registrant.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	(23)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(31.1)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(31.2)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(32.1)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification pursuant to 18&nbsp;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(32.2)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification pursuant to 18&nbsp;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	(101)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Financial statements from the Annual Report on Form 10-K of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2015, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, (iv) Consolidated Statements of Stockholders&#8217; Equity and (v) Notes to Consolidated Financial Statements.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&#8224;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Confidential treatment requested.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	#
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Confidential treatment granted.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&amp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Management contracts.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(&nbsp;)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Filed herewith.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 6PT 0.8PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	90
</P>
</EFX_EXHIBIT_INDEX>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage91"></A>
<A NAME="EXH_1070_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.70
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1070_1.JPG">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1070_2.JPG">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1070_3.JPG">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1070_4.JPG">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage95"></A>
<A NAME="EXH_1071_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: RIGHT">
	EXHIBIT 10.71
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1071_1.JPG" ALT="">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1071_2.JPG" ALT="">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/26/0001171843-16-008207_EXH1071_3.JPG" ALT="">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage98"></A>
<A NAME="EXH_21_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="MARGIN: 0">
</P>
<EFX_SUBSIDIARIES>
<A NAME="FIS_SUBSIDIARIES"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0">
<B>
	Exhibit 21
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 24PT 0 0">
<B>
	Subsidiaries of the Registrant
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<B>
	Subsidiary
</B>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 42%; TEXT-ALIGN: CENTER">
<B>
	Jurisdiction of
</B>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Incorporation
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 9%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	JPR Royalty Sub LLC
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Delaware
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	BioCryst UK Limited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	United Kingdom
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_SUBSIDIARIES>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage99"></A>
<A NAME="EXH_23_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0">
<B>
	Exhibit 23
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Consent of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	We consent to the incorporation by reference in the following Registration Statements:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-120345, 333-39484 and 333-30751) pertaining to the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated as of March&nbsp;8, 2004;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-8 No.&nbsp;333-90582) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-8 No.&nbsp;333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, which amended and restated the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan as of May&nbsp;17, 2006;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-3 No.&nbsp;333-145638) pertaining to the registration of up to 8,140,000&nbsp;shares of common stock;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-8 No.&nbsp;333-145627) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan as amended and restated effective March 2007 and Employment Letter Agreement dated April&nbsp;2, 2007 between BioCryst Pharmaceuticals, Inc. and David McCullough;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-3 No.&nbsp;333-153084) for the registration of 3,335,408&nbsp;shares of BioCryst Pharmaceuticals, Inc. common stock and 3,159,895 warrants to purchase common stock of BioCryst Pharmaceuticals, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-8 No.&nbsp;333-152570) pertaining to the BioCryst Pharmaceutical, Inc. Stock Incentive Plan, as amended and restated effective February&nbsp;28, 2008 and the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated effective February&nbsp;28, 2008;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-8 No.&nbsp;333-167830) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated effective March&nbsp;31, 2010 and the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated effective March&nbsp;31, 2010;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form&nbsp;S-8 No.&nbsp;333-176096) pertaining to the BioCryst Pharmaceutical, Inc. Stock Incentive Plan, as amended and restated effective February&nbsp;17, 2011;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form S-3 No. 333-192117) for the registration of up to $125 million of BioCryst Pharmaceuticals, Inc. common stock, preferred stock, depository shares, stock purchase contracts, warrants or units;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form S-8 No. 333-187193) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and Employee Stock Purchase Plan, each as amended and restated effective March 29, 2012;
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form S-8 No. 333-195869) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and Employee Stock Purchase Plan, each as amended and restated effective March 8, 2014;
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-RIGHT: 0.8PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 92%; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Statement (Form S-8 No. 333-202466) for the registration of up to $150 million of BioCryst Pharmaceuticals, Inc. common stock, preferred stock, depositary shares, stock purchase contracts, warrants or units;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	of our reports dated February 26, 2016 with respect to the consolidated financial statements
	of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst Pharmaceuticals,
	Inc. included in this Annual Report (Form 10-K) of BioCryst Pharmaceuticals, Inc. for the year ended December&nbsp;31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%">
	/s/&nbsp;Ernst&nbsp;&amp; Young LLP
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Raleigh, North Carolina
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	February 26, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage100"></A>
<A NAME="EXH_311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0">
<B>
	Exhibit&nbsp;31.1
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 24PT 0 0 24PT">
<B>
	CERTIFICATIONS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 12PT 0 0 12PT">
	I, Jon P. Stonehouse, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K
	of BioCryst Pharmaceuticals, Inc.;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	2.&nbsp;Based on my knowledge, this report does not contain
	any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
	circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	3.&nbsp;Based on my knowledge, the financial statements, and
	other financial information included in this report, fairly present in all material respects the financial condition, results of
	operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	4.&nbsp;The registrant&rsquo;s other certifying officer(s) and
	I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
	and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for
	the registrant and have:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	a)&nbsp;designed such disclosure controls and procedures, or
	caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
	to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
	the period in which this report is being prepared;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	b)&nbsp;designed such internal control over financial reporting,
	or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
	with generally accepted accounting principles;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	c)&nbsp;evaluated the effectiveness of the registrant&rsquo;s
	disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
	and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	d)&nbsp;disclosed in this report any change in the registrant&rsquo;s
	internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
	fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
	the registrant&rsquo;s internal control over financial reporting;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	5.&nbsp;The registrant&rsquo;s other certifying officer(s) and
	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
	and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	a)&nbsp;all significant deficiencies and material weaknesses
	in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
	ability to record, process, summarize and report financial information;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	b)&nbsp;any fraud, whether or not material, that involves management
	or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Jon P. Stonehouse
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Jon P. Stonehouse
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
	Chief Executive Officer
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0.25IN 0 0 0.25IN">
	Date: February 26, 2016
</P>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage101"></A>
<A NAME="EXH_312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0">
<B>
	Exhibit&nbsp;31.2
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 24PT 0 0 24PT">
<B>
	CERTIFICATIONS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 12PT 0 0 12PT">
	I, Thomas R. Staab II, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K
	of BioCryst Pharmaceuticals, Inc.;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	2.&nbsp;Based on my knowledge, this report does not contain
	any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
	circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	3.&nbsp;Based on my knowledge, the financial statements, and
	other financial information included in this report, fairly present in all material respects the financial condition, results of
	operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	4.&nbsp;The registrant&rsquo;s other certifying officer(s) and
	I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
	and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for
	the registrant and have:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	a.&nbsp;designed such disclosure controls and procedures, or
	caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
	to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
	the period in which this report is being prepared;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	b.&nbsp;designed such internal control over financial reporting,
	or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
	with generally accepted accounting principles;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	c.&nbsp;evaluated the effectiveness of the registrant&rsquo;s
	disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
	and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	d.&nbsp;disclosed in this report any change in the registrant&rsquo;s
	internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
	fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
	the registrant&rsquo;s internal control over financial reporting;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 6PT">
	5.&nbsp;The registrant&rsquo;s other certifying officer(s) and
	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
	and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	a.&nbsp;all significant deficiencies and material weaknesses
	in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
	ability to record, process, summarize and report financial information;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 6PT 0 0 23PT">
	b.&nbsp;any fraud, whether or not material, that involves management
	or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Thomas R. Staab II
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Thomas R. Staab II
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
	Chief Financial Officer and Treasurer
<BR>
	(Principal Financial Officer)
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0.25IN 0 0 0.25IN">
	Date: February 26, 2016
</P>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage102"></A>
<A NAME="EXH_321_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0">
<B>
	Exhibit&nbsp;32.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	CERTIFICATION PURSUANT TO
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	18&nbsp;U.S.C. SECTION&nbsp;1350,
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	AS ADOPTED PURSUANT TO
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	In connection with the Annual Report of BioCryst Pharmaceuticals, Inc.
	(the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ending December&nbsp;31, 2015 as filed with the Securities and Exchange
	Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify,
	pursuant to 18&nbsp;U.S.C. &sect;&nbsp;1350, as adopted pursuant to &sect;&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to
	the best of my knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	(1)&nbsp;The Report fully complies with the requirements of section&nbsp;13(a)
	or 15(d) of the Securities Exchange Act of 1934;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	(2)&nbsp;The information contained in the Report fairly presents,
	in all material respects, the financial condition and results of operations of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Jon P. Stonehouse
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0">
	Jon P. Stonehouse
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0">
	Chief Executive Officer
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	February 26, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	This certification is furnished with this Report on Form&nbsp;10-K pursuant
	to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed
	by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
	Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended,
	or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
</P>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage103"></A>
<A NAME="EXH_322_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0">
<B>
	Exhibit&nbsp;32.2
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	CERTIFICATION PURSUANT TO
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	18&nbsp;U.S.C. SECTION&nbsp;1350,
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	AS ADOPTED PURSUANT TO&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	In connection with the Annual Report of BioCryst Pharmaceuticals, Inc.
	(the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ending December&nbsp;31, 2015 as filed with the Securities and Exchange
	Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Thomas R. Staab, II, Chief Financial Officer of the Company,
	certify, pursuant to 18&nbsp;U.S.C. &sect;&nbsp;1350, as adopted pursuant to &sect;&nbsp;906 of the Sarbanes-Oxley Act of 2002,
	that, to the best of my knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	(1)&nbsp;The Report fully complies with the requirements of section&nbsp;13(a)
	or 15(d) of the Securities Exchange Act of 1934;&nbsp;and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	(2)&nbsp;The information contained in the Report fairly presents,
	in all material respects, the financial condition and results of operations of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0 0 0 23PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/&nbsp;Thomas R. Staab II&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0">
	Thomas R. Staab II&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0">
	Chief Financial Officer and Treasurer&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0">
	(Principal Financial Officer)
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0 1.6PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	February 26, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	This certification is furnished with this Report on Form&nbsp;10-K pursuant
	to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed
	by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
	Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended,
	or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
</P>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 23PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
